Receptor Mediated Adhesion of Circulating Cells In Immune Cell Interaction and Cancer by Cao, Thong
Receptor Mediated Adhesion of Circulating Cells  
In Immune Cell Interaction and Cancer 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy 
 
 
 
 
 
by 
Thong Cao 
August 2019  
   
 
 
 
 
 
 
 
 
 
© 2019 Thong Cao 
 
 
 
 
 
 
 
 
 
  
Receptor Mediated Adhesion of Circulating Cells 
In Immune Cell Interaction and Cancer 
 
Thong Cao 
Cornell 2019 
 
Circulating tumor cells (CTCs) disseminating from primary tumor sites travel to distant 
organs and form secondary tumor sites, known as metastasis. After leaving the primary 
tumor microenvironment, CTCs enter the circulatory system where they routinely 
interact with immune cells. This interaction can paradoxically result in both limiting or 
promoting the metastatic potential of CTCs. The final steps of metastasis involve CTCs 
invaginating into the underlining tissue and forming secondary tumor sites. One 
plausible mechanism of CTCs leaving the circulatory system involves a similar process 
to leukocyte homing - selectin-mediated interaction. The scope of the work presented 
here can be divided into two parts: (a) exploiting the naturally occurring immune 
response called NETosis when neutrophils come into contact with cancer cells as a form 
of cancer therapy, and (b)  gaining a better understanding of the mechanism of selectin-
ligand interaction that playing a pivotal role in cancer metastasis and leukocyte homing.           
Immunotherapy is an emerging powerful clinical strategy for cancer therapy. NETosis 
is an innate immune response elicited by activated neutrophils to fight microbial 
infections. Activated neutrophils release DNA fibers decorated with anti-microbial 
proteins called neutrophil extracellular traps (NETs) into the extracellular space to trap 
   
and kill surrounding microbes. Here, we show tumor-derived IL-8 released by cancer 
cells also activates the release of NETs. Until now, there have been no existing 
technologies that leverage NETs as an anti-tumor drug delivery vehicle. In this study, 
we describe the re-engineering of neutrophils to express an apoptosis-inducing chimeric 
protein, supercharged eGFP-TRAIL, on NETs that can ensnare and kill tumor cells 
while retaining all of their anti-microbial capabilities. We observed significant TRAIL-
induced apoptosis in tumor cells captured by TRAIL-decorated NETs. This work 
demonstrates NETs as a promising technology to deliver protein in response to local 
cytokine signals. 
The 3-member (E-, P-, L-) selectin family of cell adhesion molecules facilitates initial 
leukocyte tethering and subsequent cell rolling during the early stages of the 
inflammatory response via binding to glycoproteins expressing sialyl LewisX and sialyl 
LewisA (sLeX/A) to sites of inflammation and trauma. The extracellular 
microenvironments at these sites often become acidic. We investigated the influence of 
slightly acidic pH on the binding dynamics of selectins (P-, L-, and E-selectin) to P-
selectin glycoprotein ligand-1 (PSGL-1) via computational modeling (molecular 
dynamics) and experimental rolling assays under shear in vitro. The P-selectin/PSGL-1 
binding is strengthened at acidic pH, as evidenced by the formation of a new hydrogen 
bond (seen computationally) and the observed decrease in the rolling velocities of model 
cells. In the case of L-selectin/PSGL-1 binding dynamics, the binding strength and 
frequency increase at acidic pH, as indicated by the greater cell-rolling flux of 
neutrophils and slower rolling velocities of L-selectin-coated microspheres, 
respectively. The cell flux is most likely due to an increased population of L-selectin in 
   
the high-affinity conformation as pH decreases, whereas the velocities are due to 
increased L-selectin/PSGL-1 contacts. In contrast to P- and L-selectin, the E-
selectin/PSGL-1 binding does not exhibit significant changes at acidic pH levels, as 
shown both experimentally and computationally.  
We also investigated the allosteric influence of E-selectin’s structure to ligand binding 
mechanics. Existing crystal structures of the extracellular lectin/EGF-like domain of E-
selectin complexed with sLeX have revealed that E-selectin can exist in two 
conformation states, a low affinity (bent) conformation, and a high affinity (extended) 
conformation. The differentiating characteristic of the two conformations is the 
interdomain angle between the lectin and the EGF-like domain. Using molecular 
dynamics (MD) simulations we observed that in the absence of tensile force E-selectin 
undergoes spontaneous switching between the two conformational states at equilibrium. 
A single amino acid substitution at residue 2 (serine to tyrosine) on the lectin domain 
favors the extended conformation. Steered molecular dynamics (SMD) simulations of 
E-selectin and PSGL-1 in conjunction with experimental cell adhesion assays show a 
longer binding lifetime of E-selectin (S2Y) to PSGL-1 compared to wildtype protein.  
The findings in this study advance our understanding into how the structural makeup of 
E-selectin allosterically influences its adhesive dynamics
.  
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CHAPTER 1 
Portions of this chapter were published in Annual Review of Biomedical Engineering 
(1). 
INTRODUCTION  
Early diagnosis in most types of cancer remains challenging due to the lack of symptoms 
in the early stage and the small size of the primary tumor. For instance, mammography, 
the most common screening tool for the detection of early-stage breast cancers, can detect 
on average 80–90% of breast cancers at an early stage in women without symptoms, and 
reduces the risk of death by 15% in all women screened. Mammography is a somewhat 
accurate screening tool, but the rate of false negatives remains around 20% and the rate 
of false positives is more than 30% (2). Mammography also detects indolent localized 
cancers that may not require treatment (3). In studies of early detection of lung cancer, 
computed tomography (CT) reduces mortality by 7–20% but has a low screening 
accuracy (96% false positive) (4). Moreover, the radiation from CT scans gives rise to 
long-term risk for some cancers (5). In another example, prostate-specific antigen (PSA) 
has been used for the early detection of prostate cancer, but the overdiagnosis rate and 
whether it contributes to a reduction in deaths remain unknown (6).  
Before cancer metastasizes, cancer cells are disseminated from the primary tumor site to 
remote sites via blood circulation (Figure 1.1). Circulating tumor cells (CTCs) were first 
discovered in 1869 during an autopsy of a metastatic cancer patient by Ashworth (7), who 
observed that the cancer cells in a site distant from the tumor resembled the original 
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tumor. This observation implied that in order for the cancer cells to have reached the 
distant site, they would have had to be transported there through the blood. Ever since, 
CTCs have been considered an important factor in metastasis and a primary cause of 
deaths attributable to cancer.  
 
Figure 1.4: Cancer metastasis involving the detachment of circulating tumor cells (CTCs) 
from the primary tumor and their invasion into the circulation, survival in the circulation, 
extravasation, and proliferation. Abbreviations: EMT, epithelial-to-mesenchymal 
transition; MET, mesenchymal-to-epithelial transition. Adapted from E. Lin, T. Cao et 
al. Annu. Rev. Biomed. Eng. 2018. 20:329–52.  
Metastasis can be described as a five-step process (Figure 1.1): (a) Cancer cells detach 
from the primary tumor, (b) invade the blood circulation, (c) survive in circulation, (d) 
extravasate into distant organs, and (e) proliferate at the secondary site(s). CTCs found in 
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Cancer metastasis involving the detachment of circulating tumor cells (CTCs) from the primary tumor and their invasion into the
circulation, survival in the circulation, extravasation, and proliferation. Abbreviations: EMT, epithelial-to-mesenchymal transition;
MET, mesenchymal-to-epithelial transition.
9, 14–17). The potential use of CTCs in many research areas has acquired great momentum in
recent years. Developments include the selection of neoadjuvant and adjuvant therapy, detection
of recurrent disease, examination of pharmacodynamic biomarkers, and identification of novel
therapeutic targets, enabling a personalized therapeutic approach (12, 13, 18, 19, 20, 21).
Compared with traditional tissue biopsy, which is an invasive procedure and presents a static
“snapshot” of the tumor, liquid biopsy involving CTC and/or circulating tumor DNA (ctDNA)
analyses is noninvasive and can provide real-time information about the disease burden, the evo-
lution of the tumor, and the tumor’s heterogeneity (22). More specifically, CTCs contain in-
formation related to the initiation of metastasis, whereas ctDNA is more representative of the
bulk of the metastatic tumor (22). Although intratumor heterogeneity is widely recognized as a
primary way to reduce the effectiveness of molecular targeted therapy, thorough investigation of
such heterogeneity remains challenging due to th difficulty of p rformin multiple tissue biop-
sies to acquire spatial and temporal samples (23). The molecular and genetic profiling of CTCs
represents a possible alternative to study tumor subpopulations during disease progression and to
monitor changes in response to therapy.
CTCs are strong prognostic and diagnostic factors because they are present in early disease
progression (24). Several studies have detected CTCs in blood in early-stage cancer. For example,
Stott et al. (17) detectedCTCs in patients with localized prostate cancer, Zhang et al. (25) extracted
CTCs from patients with early-stage lung cancer, and Murlidhar et al. (26) showed the presence
of CTCs in early-stage lung cancer not only in peripheral blood but also in pulmonary veins.
www.annualreviews.org • Circulating Tumor Cells 331
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the peripheral blood of cancer patients often indicate metastasis (8, 9). CTCs have clinical 
potential as prognostic biomarkers to predict treatment efficacy, progression-free 
survival, and overall survival in patients (10–14). There is increasing evidence that CTCs 
that entered the circulation could be a good surrogate biomarker not only for prognosis 
but also for detection and monitoring of disease (10, 15–18). The potential use of CTCs 
in many research areas has acquired great momentum in recent years. Developments 
include the selection of neoadjuvant and adjuvant therapy, detection of recurrent disease, 
examination of pharmacodynamic biomarkers, and identification of novel therapeutic 
targets, enabling a personalized therapeutic approach (13, 14, 19–22).  
Compared with traditional tissue biopsy, which is an invasive procedure and presents a 
static “snapshot” of the tumor, liquid biopsy involving CTC and/or circulating tumor 
DNA (ctDNA) analyses is noninvasive and can provide real-time information about the 
disease burden, the evolution of the tumor, and the tumor’s heterogeneity (23). More 
specifically, CTCs contain in- formation related to the initiation of metastasis, whereas 
ctDNA is more representative of the bulk of the metastatic tumor. Although intratumor 
heterogeneity is widely recognized as a primary way to reduce the effectiveness of 
molecular targeted therapy, thorough investigation of such heterogeneity remains 
challenging due to the difficulty of performing multiple tissue biopsies to acquire spatial 
and temporal samples (24). The molecular and genetic profiling of CTCs represents a 
possible alternative to study tumor subpopulations during disease progression and to 
monitor changes in response to therapy.  
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CTCs are strong prognostic and diagnostic factors because they are present in early 
disease progression (25). Several studies have detected CTCs in blood in early-stage 
cancer. For example, Stott et al. (15) detected CTCs in patients with localized prostate 
cancer, Zhang et al. (25) extracted CTCs from patients with early-stage lung cancer, and 
Murlidhar et al. (26) showed the presence of CTCs in early-stage lung cancer not only in 
peripheral blood but also in pulmonary veins.  
CTC enumeration is a powerful tool in early screening, monitoring of disease progression 
and treatment, and indication of cancer relapse (27). CTCs also have great potential to 
provide clinical and therapeutic information when combined with downstream analysis. 
Some studies have suggested that CTC enumeration alone is not sufficient to guide 
therapeutic decisions (28) but that molecular analysis of CTCs should be performed to 
determine how to target therapy (29). Mutations in genes such as KRAS, EGFR, and 
HER2 and in the estrogen receptor (ER) genes can be identified through the screening of 
CTCs (30). The differences between individual CTCs and the primary tumor may enable 
new insights through the comparison of CTC genomes with those of the primary and 
metastatic tumors (27). RNA profiling or sequencing on single or pooled CTCs can 
provide extensive information to identify signaling pathways and splice variants relevant 
to metastatic potential and therapy resistance (31). Ex vivo culture of patient-derived 
CTCs can be adopted in tests of drug efficacy (32) and can enable multiplexed proteomic 
analyses of CTCs (33).  
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1.1 CIRCULATING TUMOR CELLS AS A THERAPEUTIC TARGET  
Cancer therapies that target CTCs are compelling, considering that more than 90% of 
deaths due to cancer are related to metastasis (34). Metastasis begins when a small 
population of tumor cells, namely CTCs, break away from the primary tumor site and 
intravasate into the peripheral circulation (35, 36). Once in the circulation, CTCs travel 
to distant sites where they tether, roll, and eventually extravasate into the underlying 
tissue in a selectin-dependent manner (37). Ultimately, metastasizing cancer cells can 
form secondary tumors. Although conventional surgery and radiation may be effective at 
excising primary tumors, secondary tumors are much smaller and more difficult to detect 
until they prove fatal. Therefore, the development of technologies that directly target 
CTCs before they have the chance to form secondary tumors could potentially reduce 
metastasis-related deaths.  
Many cancer types metastasize into the lymph nodes, as well as the circulatory system 
(38). At first glance, tumor cells engrafting in the lymph nodes seems counterintuitive, 
since the lymph nodes are epicenters of immune cell congregation and 
immunosurveillance. However, tumor cells can release tumor-associated factors that 
convert the immunogenic microenvironment of the lymph nodes into an 
immunosuppressive state that can tolerate and even promote the localization of 
metastasizing cancer cells (39). The presence of cancer cells in the lymph nodes 
necessitates therapeutics that can not only selectively target cancer cells in lymph nodes 
but also reverse the immunosuppressive state of the lymph nodes.  
  6 
1.2 THERAPEUTICS DIRECTED AT CIRCULATING TUMOR CELLS  
Because tumor metastasis is responsible for more than 90% of cancer-related deaths and 
most distant metastases are formed by tumor cells leaving the primary tumor 
microenvironment and intravasating into the circulatory system, anti-CTC therapeutics 
have the potential to neutralize cancer metastasis and reduce cancer-related deaths (40). 
A straightforward approach to reducing metastasis and cancer-related deaths is to remove 
CTCs from the circulation of metastasizing patients. However, two main challenges faced 
by all CTC-capturing techniques are the rarity of these cells and the lack of a unique 
identifiable marker. The number of CTCs is relatively low in circulation—around 1–100 
CTCs per milliliter of blood or approximately 1–100 CTCs per 106 –107 leukocytes (8, 
41). Existing CTC isolation techniques, including gradient centrifugation, microfiltration, 
and EpCAM antibody targeting, are hampered by the limited volume of blood that can be 
processed per trial (10–50 mL) and by a high background level of contaminating 
leukocytes that routinely reduces the purity of the CTCs to below 1% (17, 42–44). 
Therefore, any CTC selection technique must be able to process large volumes of blood 
while attaining high purity.  
A recently proposed CTC removal process consisting of a sequential combination of two 
semiautomated technologies—leukapheresis followed by counterflow centrifugation 
elutriation— aims to address the above-described limitations (45, 46). Leukapheresis is a 
well-established density filtration technology that is used clinically to harvest peripheral 
blood mononuclear cells (PBMCs) from whole blood. Importantly, it can process the 
entire blood volume of a patient multiple times over in a single session. Because CTCs 
  7 
and PBMCs have comparable density and size, leukapheresis has been used to isolate 
CTCs from metastatic patients, yielding comparable results to other CTC enrichment 
techniques (41, 47).  
Following leukapheresis, the CTC isolation purity can be further improved with 
elutriation. Elutriation is a process that is used to separate the subpopulations, primarily 
monocytes, of isolated PBMCs by their size, and has been used to purify monocytes from 
dendritic cells (DCs) for immunotherapy applications (48, 49). The size of CTCs can be 
similar to that of monocytes. Thus, the enriched population of monocytes after elutriation 
is expected to contain CTCs as well. The combination of leukapheresis and elutriation of 
10 L of blood spiked with CaOV-3 tumor cells yielded enrichment of up to 78% CTCs 
(45). CTCs with established surface markers (EpCAM, cytokeratin, and CD45− ) can 
further be enriched using fluorescence-activated cell sorting (50, 51).  
An in vivo photoacoustic flow cytometry system was recently developed to detect and 
ablate CTCs in tumor-bearing mice in a label-free manner (52–54). The advantage of this 
technology is that it can process large volumes of blood; specifically, 5 L of blood can be 
processed in under 2 h. Also, the technique has a high threshold sensitivity, as it is able 
to detect a single CTC from 107 normal blood cells (55–57). However, this technique has 
been tested only in a melanoma-bearing mouse model (52).  
 
 
 
  8 
1.3 TRAIL-BASED CIRCULATING TUMOR CELL THERAPEUTICS  
After CTCs have entered the circulatory system, they travel to distant organs, extravasate 
out of blood vessels and into the underlying tissue and form secondary tumors. Similar to 
circulating leukocytes, CTCs use interactions between selectins and ligands to tether, roll, 
and arrest onto the vascular wall before subsequent extravasation into the distal site (37, 
58–60). This knowledge of the molecular mechanisms involved in CTC extravasation has 
led to the development of a selectin-based implantable shunt device that can capture and 
eradicate CTCs (61). The device is a microtube with its luminal surface functionalized 
with E-selectin molecules and tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL) to facilitate CTC rolling and eventual tumor cell apoptosis, respectively.  
TRAIL has generated extensive research attention as a cancer therapeutic because it can 
selectively induce apoptosis in a variety of tumor cell lines while sparing most normal 
cells. TRAIL induces cell death in target cells through binding to death receptors DR4 
and DR5, giving rise to the extrinsic caspase-dependent apoptosis signaling pathway (62). 
Although the clinical success of TRAIL therapy for solid tumors has been somewhat 
limited because some cancer cell types exhibit varying degrees of TRAIL resistance, 
TRAIL-resistant cancer cells become more sensitive to TRAIL after they have detached 
from the extracellular matrix (63). Moreover, tumor cells become more “sensitized” to 
TRAIL when exposed to fluid shear stress (64). In the circulatory system, where wall 
shear stress can range from 0.5 to 4.0 dyne/cm2 in the venous circulation and up to 30.0 
dyne/cm2 in the arterial circulation, CTCs experience a significantly higher shear 
environment than cells in the primary tumor site (65). Furthermore, CTC sensitivity to 
  9 
caspase-dependent apoptosis is positively correlated with fluid shear stress level and 
exposure time (64, 66, 67). Thus, the natural detachment of metastatic CTCs from the 
primary tumor microenvironment and into the higher shear environment of the circulatory 
system makes them especially vulnerable to TRAIL-based therapy.  
 
Figure 1.5: E-selectin (ES)- and tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL)-coated liposomes induce apoptosis of lodged COLO 205 cells in the lungs. (a) 
Schematic of a mouse lung and a two-photon excited fluorescence (2PEF) image of 
lodged COLO 205 cells (green) in the lung tissue (yellow). (b) 2PEF images of lodged 
COLO 205 cells (green) stained with Annexin V apoptosis marker (red) in different 
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the venous circulation and up to 30.0 dyn/cm2 in the arterial circulation, CTCs experience a
significantly higher shear environment than cells in the primary tumor site (95). Furthermore,
CTC s nsitivity to c spase-dependent apoptosis is positively correlated with fluid hear stress
level and exposure time (94, 96, 97). Thus, the natural detachment of metastatic CTCs from
the primary tumor microenvironment and in o the higher shear environment of the circulatory
system makes them especially vulnerable to TRAIL-based therapy.
More recently, lip somes functionalized wi TRAIL and E-selectin olecules r adily attach
onto circulating leukocytes under flow, thus turning these leukocytes into “unnatural killer cells”
within the circulatory syst m that can induce apoptosis in any CTCs the come into contact with
(98, 99). More importantly, mice bearing colorectal CTCs experienced a reduction of tumor cells
lodged in the lungs as well as a significantly higher rate of apoptosis (Figure 3).
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Figure 3
E-selectin (ES)- and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-coated liposomes
induce apoptosis of lodged COLO 205 cells in the lungs. (a) Schematic of a mouse lung and a two-photon
excited fluorescence (2PEF) image of lodged COLO 205 cells ( green) in the lung tissue ( yellow). (b) 2PEF
images of lodged COLO 205 cells ( green) stained with Annexin V apoptosis marker (red ) different
experimental groups in lung tissue. Red and blue arrows mark apoptotic and nonapoptotic cells, respectively.
White circles mark regions of autofluorescence. (c) Arrested COLO 205 cell density in lung tissue of
different experimental groups. (d ) Percentage of apoptotic COLO 205 cells of different experimental groups.
In panels c and d, red, green, and blue dots represent distinct animals in the studies. Gray asterisks represent
statistical significance: ∗p < 0.01, ∗∗p < 0.0001 (one-way ANOVA with Tukey posttest). Bars represent
(from top to bottom): maximum, Q3, median, Q1, and minimum. Abbreviation: sTRAIL, soluble TRAIL.
Adapted with permission from Reference 98.
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experimental groups in lung tissue. Red and blue arrows mark apoptotic and 
nonapoptotic cells, respectively. White circles mark regions of autofluorescence. (c) 
Arrested COLO 205 cell density in lung tissue of different experimental groups. (d) 
Percentage of apoptotic COLO 205 cells of different experimental groups. In panels c 
and d, red, green, and blue dots represent distinct animals in the studies. Gray asterisks 
represent statistical significance: ∗p < 0.01, ∗∗p < 0.0001 (one-way ANOVA with Tukey 
posttest). Bars represent (from top to bottom): maximum, Q3, median, Q1, and minimum. 
Abbreviation: sTRAIL, soluble TRAIL. Adapted from E. Lin, T. Cao et al. Annu. Rev. 
Biomed. Eng. 2018. 20:329–52.  
More recently, liposomes functionalized with TRAIL and E-selectin molecules readily 
attach onto circulating leukocytes under flow, thus turning these leukocytes into 
“unnatural killer cells” within the circulatory system that can induce apoptosis in any 
CTCs they come into contact with (68, 69). More importantly, mice bearing colorectal 
CTCs experienced a reduction of tumor cells lodged in the lungs as well as a significantly 
higher rate of apoptosis (Figure 1.2).  
Aside from leukocytes, platelets also routinely interact with CTCs in the bloodstream, 
making them attractive candidates for therapeutic vehicles. Platelets facilitate the 
progression of metastasis through CTC–platelet aggregation (70–72). They do so in 
multiple ways: They protect CTCs by shielding antigen-derived epitopes on tumor cells 
that are normally recognized by circulating immune cells and increase CTC extravasation 
potential by inducing an epithelial- to-mesenchymal-like transition (73–76). Multiple 
studies have introduced platelet-targeting liposomes that contain platelet aggregation 
  11 
inhibitors to prevent CTC–platelet aggregation (77–79). As an alternative to existing anti-
aggregation therapies, several studies have proposed anti-tu moral therapeutics that 
exploit the natural tendency of CTC–platelet aggregation. For example, Li et al. (80, 81) 
engineered platelets to express TRAIL on their plasma membrane (Figure 1.3). With this 
technique, hematopoietic stem and progenitor cells were transduced with lentiviral 
vectors containing the TRAIL gene and a megakaryocyte-specific promoter (Figure 1.4). 
Sixty days after bone marrow transplantation, bioluminescence images revealed a 
significant reduction in metastasis in mice with TRAIL-expressing platelets (Figure 1.5). 
From the standpoint of CTC therapeutics, platelets are increasingly being explored as 
potential antitumoral vehicles due to their interactions with CTCs (82).  
  12 
 
Figure 1.6: Schematic of engineered platelets expressing tumor necrosis factor–related 
apoptosis-inducing ligand (TRAIL) to kill circulating tumor cells in the circulation. 
Adapted from E. Lin, T. Cao et al. Annu. Rev. Biomed. Eng. 2018. 20:329–52.  
In patients with melanomas, carcinomas, and sarcomas, the first route of metastasis is via 
the tumor- draining lymph nodes (TDLNs) (83–85). With melanomas in particular, 80% 
of metastasizing tumor cells travel to the lymph nodes, while the remaining 20% enter 
the circulation or directly seed (86). Among patients with lung, breast, and colorectal 
cancers, around 29–37% are diagnosed with metastases in their lymph nodes (8). 
Therefore, metastatic lymph node prognosis is an important indicator of metastatic 
burden pre- and posttreatment in many types of cancer therapy (87–90). 
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Figure 4
Schematic of engineered platelets expressing tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) to kill circulating tumor cells in the circulation. Adapted with permission from Reference 110.
Aside from leukocytes, platelets also routinely interact with CTCs in the bloodstream, making
them attractive candidates for therapeutic vehicles. Platelets facilitate the progression of metas-
tasis through CTC–platelet aggregation (100–102). They do so in multiple ways: They protect
CTCs by shielding antig n-derived epitopes on tumor cells that are normally recognized by
circulating immune cells and increase CTC extravasation potential by inducing an epithelial-
to-mesenchymal-like transition (103–106). Multiple studies have introduced platelet-targeting
liposomes that contain platelet aggregation inhibitors to prevent CTC–platelet aggregation (107–
109). As an alternative to existing antiaggregation therapies, several studies have proposed antitu-
moral therapeutics that exploit the natural tendency of CTC–platelet aggregation. For example,
Li et al. (110, 111) engineered platelets to express TRAIL on their plasma membrane (Figure 4).
With this technique, hematopoietic stem and progenitor cells were transduced with lentiviral vec-
tors containing the TRAIL gene and a megakaryocyte-specific promoter (Figure 5). Sixty days
after bone marrow transplantation, bioluminescence images revealed a significant reduction in
metastasis in mice with TRAIL-expressing platelets (Figure 6). From the standpoint of CTC
therapeutics, platelets are increasingly being explored as potential antitumoral vehicles due to
their interactions with CTCs (112).
3.3. Circulating Tumor Cell Therapeutics in Tumor-Draining Lymph Nodes
In patientswithmelanomas, carcinomas, and sarcomas, the first route ofmetastasis is via the tumor-
draining lymph nodes (TDLNs) (113–116). With melanomas in particular, 80% of metastasizing
tumor cells travel to the lymph nodes, while the remaining 20% enter the circulation or directly
seed (117). Amongpatientswith lung, breast, and colorectal cancers, around29–37%are diagnosed
with metastases in their lymph nodes (67). Therefore, metastatic lymph node prognosis is an
important indicator of metastatic burden pre- and posttreatment in many types of cancer therapy
(118–121).
The lymphatic system is a network of vessels that exist throughout the interstitial space of
tissues and organs in the body. The body uses these lymphatic vessels to remove waste, toxins,
and other unwanted materials from the organs. More importantly, the vessels transport lymph,
340 Lin et al.
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Figure 1.7: Cells transduced with megakaryocyte-specific lentiviral expression vectors 
express target protein only in a lineage-specific manner. (a) Schematic of lentiviral 
vectors for expression of enhanced green fluorescent protein (eGFP) and tumor necrosis 
factor–related apoptosis-inducing ligand (TRAIL) in megakaryocytes. (b) Gene 
expression after transduction of Ubc-eGFP, αIIβ-eGFP, Ubc-TRAIL, and αIIβ-TRAIL in 
the promegakaryocytic cell line Dami and the human embryonic kidney cell line 293T. 
(c) Immunofluorescence images of surface-bound TRAIL in Ubc-TRAIL- and αIIβ-
TRAIL-transduced Dami and 293T cells. Nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI) (blue). Abbreviations: CMV, cytomegalovirus; HIV, human 
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Figure 5
Cells transduced with megakaryocyte-specific lentiviral expression vectors express target protein only in a lineage-specific manner.
(a) Schematic of lentiviral vectors for expression of enhanced green fluorescent protein (eGFP) and tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) in megakaryocytes. (b) Gene expression after transduction of Ubc-eGFP, αIIβ-eGFP,
Ubc-TRAIL, and αIIβ-TRAIL in the promegakaryocytic cell line Dami and the human embryonic kidney cell line 293T.
(c) Immunofluorescence images of surface-bound TRAIL in Ubc-TRAIL- and αIIβ-TRAIL-transduced Dami and 293T cells. Nuclei
were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Abbreviations: CMV, cytomegalovirus; HIV, human immunodeficiency
virus; WRE, woodchuck hepatitis virus posttranscriptional regulatory element. Adapted with permission from Reference 110.
a fluid containing immune cells, throughout the body to protect it from unwanted antigens. All
of the lymphatic vessels drain into lymph nodes, where innate immune response transitions into
adaptive immunity: Antigen presenting cells such as DCs and macrophages travel there to prime
naı¨ve T and B cells with the processed antigens (122). For the most up-to-date understanding of
how immune cells home to the lymph n des, see Reference 122.
Tumor cells have several means of escaping the immune response, including the production
and release of immunosuppressive factors, impairment of immune cell priming, and recruitment
www.annualreviews.org • Circulating Tumor Cells 341
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immunodeficiency virus; WRE, woodchuck hepatitis virus posttranscriptional regulatory 
element. Adapted from E. Lin, T. Cao et al. Annu. Rev. Biomed. Eng. 2018. 20:329–52. 
The lymphatic system is a network of vessels that exist throughout the interstitial space 
of tissues and organs in the body. The body uses these lymphatic vessels to remove waste, 
toxins, and other unwanted materials from the organs. More importantly, the vessels 
transport lymph, a fluid containing immune cells, throughout the body to protect it from 
unwanted antigens. All of the lymphatic vessels drain into lymph nodes, where innate 
immune response transitions into adaptive immunity: Antigen presenting cells such as 
DCs and macrophages travel there to prime na ̈ıve T and B cells with the processed 
antigens (91).  
 
Figure 1.8: Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-
expressing platelets reduce systemic metastases. (a) Schematic of TRAIL-expressing 
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Figure 6
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-expressing platelets reduce systemic metastases. (a) Schematic of
TRAIL-expressing platelet gene therapy in a PCa experimental metastasis model. (b) Liver metastatic burden in mice with TRAIL-
expressing platelets (red circles) or empty vector–transduced platelets (blue squares) on day 60 after bone marrow transplantation (BMT).
The black lines show means ± SEM (standard error of the mean). The gray asterisk indicates statistical significance: ∗p < 0.05.
(c) Bioluminescence (BLI) images of mice on day 60 after BMT. (d ) Liver samples from mice with empty vector–transduced or TRAIL-
expressing platelets. (e) Hematoxylin and eosin staining of liver sections. Abbreviations: H, hepatocytes; T, cancer cells. Adapted with
permission from Reference 110.
of suppressive immune cells instead of cytotoxic immune cells (123–125). When these cancer-
derived immunosuppressive factors drain into the lymph nodes, they can change the lymphatic
system from an immune-responsive environment into an immune-repressive one that tolerates
tumor metastasis.
Natural killer (NK) cells are innate response immune cells that reside mostly in the paracortex
of the lymph nodes. NK cells exert a natural cytotoxic effect against TRAIL-sensitive tumor
cells through their constitutive expression of TRAIL on the cell surface and on their cytoplasmic
granules, which are released during an immune response (126–128). However, tumor cells possess
many mechanisms to evade NK cell–mediated tumor cytotoxicity, including downregulation of
their expression of major histocompatibility complex (MHC) class I, shedding of ligands for
activation receptors, and secretion of inhibitory cytokines that can reduce TRAIL expression on
NK cells (68, 129–132). To overcome these limitations, researchers have explored enhancing NK
cell proliferation and cytokine production with in vivo stimulation using cytokines or ex vivo
activation/expansion methods (133–135). However, these studies were met with limited success
due to an increase in systemic toxicity, suppression by MHC molecules, and rejection from the
host (136). To enhance the intrinsic tumor-suppressing capability of NK cells in the TDLN,
342 Lin et al.
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platelet gene therapy in a PCa experimental metastasis model. (b) Liver metastatic 
burden in mice with TRAIL-expressing platelets (red circles) or empty vector–transduced 
platelets (blue squares) on day 60 after bone marrow transplantation (BMT). The black 
lines show means ± SEM (standard error of the mean). The gray asterisk indicates 
statistical significance: ∗p < 0.05. (c) Bioluminescence (BLI) images of mice on day 60 
after BMT. (d) Liver samples from mice with empty vector–transduced or TRAIL- 
expressing platelets. (e) Hematoxylin and eosin staining of liver sections. Abbreviations: 
H, hepatocytes; T, cancer cells. Adapted from E. Lin, T. Cao et al. Annu. Rev. Biomed. 
Eng. 2018. 20:329–52.  
Tumor cells have several means of escaping the immune response, including the 
production and release of immunosuppressive factors, impairment of immune cell 
priming, and recruitment of suppressive immune cells instead of cytotoxic immune cells 
(92–94). When these cancer- derived immunosuppressive factors drain into the lymph 
nodes, they can change the lymphatic system from an immune-responsive environment 
into an immune-repressive one that tolerates tumor metastasis.  
Natural killer (NK) cells are innate response immune cells that reside mostly in the 
paracortex of the lymph nodes. NK cells exert a natural cytotoxic effect against TRAIL-
sensitive tumor cells through their constitutive expression of TRAIL on the cell surface 
and on their cytoplasmic granules, which are released during an immune response (95–
97). However, tumor cells possess many mechanisms to evade NK cell–mediated tumor 
cytotoxicity, including downregulation of their expression of major histocompatibility 
complex (MHC) class I, shedding of ligands for activation receptors, and secretion of 
  16 
inhibitory cytokines that can reduce TRAIL expression on NK cells (39, 98–101). To 
overcome these limitations, researchers have explored enhancing NK cell proliferation 
and cytokine production with in vivo stimulation using cytokines or ex vivo 
activation/expansion methods (102–104). However, these studies were met with limited 
success due to an increase in systemic toxicity, suppression by MHC molecules, and 
rejection from the host (105). To enhance the intrinsic tumor-suppressing capability of 
NK cells in the TDLN,  
Chandrasekaran et al.  (106, 107) developed TRAIL-decorated liposomes that specifically 
bind to NK cells in the tumor-draining inguinal lymph node and effectively prevent the 
metastatic spread of the primary tumor (Figure 1.6). Liposomes were functionalized with 
TRAIL and anti-NK1.1 antibody via thiolation; the liposomes then selectively bound to 
  17 
NK cells (Figure 6). After 6 weeks, NK cells 
 
Figure 1.6: Pharmacokinetics of tumor necrosis factor–related apoptosis-inducing 
ligand (TRAIL)/anti-NK1.1 liposomes. (a) Schematic of liposome formulation. (b) 
Representative flow cytometry histograms showing TRAIL/anti-NK1.1 liposomes’ 
attachment level to different cell types within the lymph nodes. (c) Confocal fluorescence 
images of TRAIL/anti-NK1.1 liposomes bound to natural killer (NK) cells isolated from 
the inguinal lymph. (d) Percentage of NK cells bound with liposomes at different time 
points. Abbreviations: DC, dendritic cell; DAPI, 4′,6-diamidino-2-phenylindole; DSPE, 
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Figure 7
Pharmacokinetics of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)/anti-NK1.1
liposomes. (a) Schematic of liposome formulation. (b) Representative flow cytometry histograms showing
TRAIL/anti-NK1.1 liposomes’ attachment level to different cell types within the lymph nodes. (c) Confocal
fluorescence images of TRAIL/anti-NK1.1 liposomes bound to natural killer (NK) cells isolated from the
inguinal lymph. (d ) Percentage of NK cells bound with liposomes at different time points. Abbreviations:
DC, dendritic cell; DAPI, 4′,6-diamidino-2-phenylindole; DSPE, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine; FITC, fluorescein isothiocyanate; IgG, immunoglobulin G; mPEG,
monomethoxypoly(ethylene glycol); PC, phosphatidylcholine. Adapted with permission from Reference 138.
Chandrasekaran et al. (137, 138) developed TRAIL-decorated liposomes that specifically bind to
NK cells in the tumor-draining inguinal lymph no e and effectively prevent the metastatic spread
of the primary tumor. Liposomes were functionalized with TRAIL and anti-NK1.1 antibodies via
thiolation; the liposomes then selectively bound toNK cells (Figure 7). After 6 weeks, NK cells in
the tumor-draining inguinal lymph nodes were able to significantly suppress themetastatic burden
(Figure 8). These results substa tiate the antitumoral therapeutic p tential of NK cells in the
draining lymph nodes and elsewhere. Although NK cells naturally exhibit antitumoral capability,
they are susceptible to becoming anergic against tumor cells. Current and future NK cell–based
immunotherapymust overcomeNKcell paralysis while expanding these cells’ existing antitumoral
potential.
www.annualreviews.org • Circulating Tumor Cells 343
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1,2-distearoyl-sn-glycero-3- phosphoethanolamine; FITC, fluorescein isothiocyanate; 
IgG, immunoglobulin G; mPEG, monomethoxypoly(ethylene glycol); PC, 
phosphatidylcholine. Adapted from E. Lin, T. Cao et al. Annu. Rev. Biomed. Eng. 2018. 
20:329–52.  
in the tumor-draining inguinal lymph nodes were able to significantly suppress the 
metastatic burden (Figure 1.7). These results substantiate the antitumoral therapeutic 
potential of NK cells in the draining lymph nodes and elsewhere. Although NK cells 
naturally exhibit antitumoral capability, they are susceptible to becoming anergic against 
tumor cells. Current and future NK cell–based immunotherapy must overcome NK cell 
paralysis while expanding these cells’ existing antitumoral potential.  
  19 
 
Figure 1.7: Metastatic burden in the tumor-draining inguinal lymph nodes. (a) 
Bioluminescence (BLI) images of mice treated with tumor necrosis factor–related 
apoptosis-inducing ligand (TRAIL)/anti-NK1.1 liposomes showing a reduction of tumor 
growth in the inguinal lymph node. (b) Total tumor flux in the inguinal lymph nodes with 
time. (c) Total flux from the inguinal lymph nodes in mice from different treatment groups 
at week 2. (d ) Total flux from the inguinal lymph nodes in mice from different treatment 
groups at week 6. In panels c and d, bars represent (from top to bottom): maximum, Q3, 
median, Q1, and minimum. Plus signs represent means. In panel d, gray asterisks 
represent statistical significance: ∗p < 0.05, ∗∗p < 0.01. Abbreviations: IgG, 
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Figure 8
Metastatic burden in the tumor-draining inguinal lymph nodes. (a) Bioluminescence (BLI) images of mice treated with tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)/anti-NK1.1 liposomes showing a reduction of tumor growth in the inguinal lymph
node. (b) Total tumor flux in the inguinal lymph nodes with time. (c) Total flux from the inguinal lymph nodes in mice from different
treatment groups at week 2. (d ) Total flux from the inguinal lymph nodes in mice from different treatment groups at week 6. In panels c
and d, bars represent (from top to bottom): maximum, Q3, median, Q1, and minimum. Plus signs represent means. In panel d, gray
asterisks represent statistical significance: ∗p < 0.05, ∗∗p < 0.01. Abbreviations: IgG, immunoglobulin G; NK, natural killer; NS,
nonsignificant. Adapted with permission from Reference 138.
3.4. Antitumor Vaccines
As antigen presenting cells, DCs sample the tissue and tumormicroenvironments and phagocytose
tumor-derived antigens (139, 140). DCs have the special ability to process the phagocytosed
antigens, present them to naı¨ve T cells residing in the lymph nodes, and trigger the proliferation
of CD8+ cytotoxic T lymphocytes (CTLs) against the tumor cells in the lymph nodes (141).
Several strategies have been proposed that utilize DCs as vehicles to deliver tumor antigens to
the lymph nodes with the aim of activating or expanding the patient’s immune response against
tumor cells. One such strategy is to coadminister tumor lysates in conjunction with the potent DC
adjuvants CpG oligodeoxynucleotides so as to elicit an immune response (142, 143). However,
344 Lin et al.
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immunoglobulin G; NK, natural killer; NS, nonsignificant. Adapted from E. Lin, T. Cao 
et al. Annu. Rev. Biomed. Eng. 2018. 20:329–52. 
1.4 ANTITUMOR VACCINES  
As antigen presenting cells, DCs sample the tissue and tumor microenvironments and 
phagocytose tumor-derived antigens (108, 109). DCs have the special ability to process 
the phagocytosed antigens, present them to na ̈ıve T cells residing in the lymph nodes, 
and trigger the proliferation of CD8+ cytotoxic T lymphocytes (CTLs) against the tumor 
cells in the lymph nodes (110). Several strategies have been proposed that utilize DCs as 
vehicles to deliver tumor antigens to the lymph nodes with the aim of activating or 
expanding the patient’s immune response against tumor cells. One such strategy is to co-
administer tumor lysates in conjunction with the potent DC adjuvants CpG 
oligodeoxynucleotides so as to elicit an immune response (111, 112). However, the 
tumor-induced immunosuppressive microenvironment of the TDLNs prevents a 
sustained and robust CTL response, even in the presence of highly immunogenic antigens 
(113, 114). Interestingly, the administration of an adjuvant alone, without tumor antigen, 
is enough to elicit an immune response despite the immunosuppressive state of the 
TDLNs (115, 116). However, novel therapeutic strategies that prevent and/or reverse the 
immunosuppressive state of TDLNs may still be warranted to maximize the potential of 
antitumoral CTL responses.  
Synthetic implantable scaffolds that mimic the natural lymph nodes chemically and 
structurally and can accommodate an immunogenic microenvironment provide great 
spatiotemporal control and are promising alternative locations for immune cells to cross-
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talk, proliferate and disperse (92). Hydrogels made from monomethoxy-PEG-co-
polylactic-co-glycolic acid copolymer hydrogels release granulocyte-macrophage 
colony-stimulating factor to attract DCs into the matrix (117). Viral vectors containing 
tumor antigens are then injected locally into the implanted hydrogels to activate the 
recruited DCs. These cells then travel to the TDLNs to activate the proliferation of CTLs. 
In a different model, proposed by the Mooney group (118, 119), instead of using viral 
vectors to introduce tumor-derived antigens to DCs, the antigens and adjuvants are 
immobilized into the hydrogel matrix. These authors observed sustained DC recruitment 
into the scaffolds that resulted in a significant and sustained proliferation of antigen-
specific CTLs. These results convincingly demonstrate the superior antitumoral 
therapeutic potential of DC priming using implantable synthetic scaffolds in comparison 
to treatments without scaffolds.  
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CHAPTER 2 
Supercharged eGFP-Trail Decorated NETs to Ensnare 
and Kill Disseminated Tumor Cells 
 
2.1 INTRODUCTION 
NETosis is an innate immune response elicited by activated neutrophils to fight microbial 
infections. Activated neutrophils release DNA fibers decorated with anti-microbial 
proteins called neutrophil extracellular traps (NETs) into the extracellular space to trap 
and kill surrounding microbes. Here, we show tumor-derived IL-8 released by cancer 
cells also activates the release of NETs. Until now, there have been no existing 
technologies that leverage NETs as an anti-tumor drug delivery vehicle. In this study, we 
describe the re-engineering of neutrophils to express an apoptosis-inducing chimeric 
protein, supercharged eGFP-TRAIL, on NETs that can ensnare and kill tumor cells while 
retaining all of their anti-microbial capabilities. We observed significant TRAIL-induced 
apoptosis in tumor cells captured by TRAIL-decorated NETs. This work demonstrates 
NETs as a promising technology to deliver protein in response to local cytokine signals. 
Neutrophils play a significant role in all stages of tumorigenesis from the initial genotoxic 
insult, to metastasis to distant organs. Chronic inflammation drives neutrophils to release 
mutagenetic agents including reactive oxygen species (ROS) and hypochlorous acid 
(HOCl) that induce DNA damage and mutagenicity on surrounding cells (120–122). 
Neutrophils make up a significant percentage of white blood cells that infiltrate the tumor 
microenvironment (123). In that setting, infiltrating neutrophils continue to promote 
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tumor development by secreting pro-inflammatory and pro-angiogenesis chemokines and 
cytokines such as matrix metallopeptidase 9 (MMP9) and interleukin 6 (IL-6) (124–126). 
Tumor metastasis through hematogenous dissemination involves circulating tumor cells 
(CTCs) shedding from the primary tumor site and reaching distant organs via the 
circulatory system. In a recent study, neutrophils have been found to support CTC 
survival during hematogenous dissemination (127). Furthermore, neutrophils have been 
identified as the main driver in establishing the pre-metastatic microenvironment in 
several mouse breast cancer models (128).         
NETosis is a unique form of innate immune response elicited primarily by neutrophils to 
combat microbial infections (129). In the presence of antigens, neutrophils undergo 
NETosis by following a program of cell death and releasing condensed DNA fibers 
decorated with cationic antimicrobial proteins, collectively called NETs, into the 
extracellular space (130). Tumor cells release tumor-derived interleukin 8 (IL-8), a potent 
neutrophil chemoattractant, to increase tumor growth and metastatic potential by:  (a) 
promoting tumor neovascularization and (b) inducing infiltrating neutrophils to release 
pro-metastatic enzymes(131). Initially, NETosis was found to specifically occur in the 
presence of bacterial antigens, but here we show that tumor-derived IL-8 released by 
tumor cells also elicits NETosis in neutrophils (Figure 2.1b, c). Blocking the tumor-
derived IL-8 pathway with a small molecule, reparixin, returned NETosis back to basal 
level (Figure 2.1e). Moreover, we quantified cell-free serum DNA levels in cancer 
patients and found a significant increase in serum DNA level compared to the healthy 
cohort suggesting that NETs may also have an elevated presence in the circulatory system 
in cancer patients (Figure 2.1a). These results support previous findings that malignant 
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and non-malignant neutrophils in tumor-bearing mice have increased sensitivity toward 
undergoing NETosis (132).  Given data shown here of the ubiquitous presence of 
neutrophils in all stages of tumor development, we proposed a unique anti-tumor drug 
delivery system by exploiting the ability of neutrophils to spontaneously undergo 
NETosis in the presence of cancer cells.  
Although NETs have been shown to ensnare cancer cells, they lack the ability to kill 
cancer cells. More insidiously, trapped tumor cells show increased metastatic potential 
(133). In the current study, we proposed to re-engineer human neutrophils to express 
NETs decorated with an apoptosis-inducing peptide, TRAIL, that could selectively 
destroy cancer cells during NETosis. TRAIL is a small cytokine expressed by most cell 
types that selectively induces apoptosis in tumor cells overexpressing death receptors 
while sparing healthy cells (68, 80). In this model, we successfully knocked in our gene 
of interest (GOI), expressing the chimeric protein eGFP-TRAIL, into the safe harbor site 
AAVS1 on chromosome 19 of the proto-neutrophilic cell line PLB-985 using the 
CRISPR/Cas system (Figure 2a,b). PLB-985 is a leukemic cell line that can be induced 
into neutrophil-like cells capable of undergoing NETosis (134, 135). Aside from serving 
as a fluorescent marker, eGFP serves a more important function by selectively allowing 
the chimeric protein to electrostatically bind to the DNA fibers of NETs during NETosis 
(Figure 2a). By modifying the surface charge of eGFP to become increasingly more 
positive, we were able to increase its avidity to the negatively-charged DNA fibers in a 
charge-dependent manner (Supp. Figure 2.1). The transfected cells stably expressed 
eGFP-TRAIL-decorated NETs during NETosis (Figure 2.2e-f). mRNA data showed 
successful expression of the transgene (Figure 2.2c-d). Immunostaining scanning electron 
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microscopy with TRAIL antibody-conjugated gold nanoparticles of NET DNA fibers 
revealed that eGFP-TRAIL protein molecules are decorated along the DNA fibers (Figure 
2.2f).  
PLB-985 derived neutrophils expressing NETs decorated with eGFP-TRAIL co-cultured 
with multiple human tumor cell lines showed significant apoptosis-inducing potential. In 
COLO-205, after 16 h of co-culture, 7% and 12% of the tumor cells underwent early and 
late apoptosis, respectively, while over 55% of the population were classified as necrotic 
(Figure 2.3a).  In the presence of eGFP-decorated NETs we observed an over 60% kill 
rate of cancer cells in the three cell lines SW620, COLO 205 and MDA-MB-213 (Figure 
2.3b). SEM images clearly showed significant NETosis when neutrophils were co-
cultured with tumor cells. However, only when NETs were decorated with eGFP-TRAIL 
did the tumor cells undergo apoptosis as evident by membrane blebbing (Figure 2.3c).  
The constant presence of neutrophils near tumor cells in all stages of cancer development 
and in conjunction with the unique ability of neutrophils to undergo NETosis in the 
presence of cancer cells, make neutrophils a promising candidate for the delivery of 
cancer therapeutics. Here we introduced a novel form of cancer therapy by leveraging 
these unique aspects of neutrophils by re-engineering the cell to express a chimeric eGFP-
TRAIL protein. This form of treatment exemplifies the potential of employing 
neutrophils as a drug delivery vehicle that, until now, has been largely unexplored. 
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2.2 METHODS 
Cell culture and differentiation 
The acute myeloid leukemia PLB-985 cell line (derivative of HL-60) stably expressing 
Cas9 protein was a generous gift from the Collins Lab (University of California, Davis). 
The cells were cultured in RPMI 1640 media supplemented with 2 mM L-glutamine, 25 
mM HEPES, 10% (v/v) FBS, and 2  g/mL Blastincidin at 37C and 5% CO2. Cultured 
cells were regularly tested for mycoplasma using the Universal Mycoplasma Detection 
Kit (ATCC 30-1012K). 
Neutrophil differentiation of logarithmically growing PLB-985 cells was induced by 
reduction of FBS to 5% and supplementation of 0.5% (vol/vol) DMF. After 3 days, an 
equivalent of the initial volume of differentiating medium was added and the 
differentiation continued until day 7. 
 
Plasma cell free DNA isolation and quantification 
 
Plasma was isolated from whole blood of cancer patients and healthy donors by 
centrifugation. To 1 mL of plasma, 100  l of Tris-HCl (pH 8.0) buffer containing 250 
mM EDTA, 750 mM NaCl, 100 g/L of sodium dodecyl sulfate and 20 mg/mL of 
proteinase K was added and incubated for 2 h at 56℃. Next proteins were precipitated 
with 200  l of 6M NaCl solution. The cell-free DNA (cfDNA) was extracted from the 
supernatant using phenol-chloroform-isoamyl alcohol (25:24:1) followed by ethanol 
precipitation. DNA concentration was quantified using nano-drop.  
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Vector design 
pAAVS1-eGFP-TRAIL was constructed starting with the plasmid template of pMK232 
(Addgene 72834) containing the AAVS1 homology arms. The eGFP-TRAIL sequence 
was inserted downstream of the CMV promoter. pX330-U6-AAVS1 was constructed 
using the plasmid template of pX330 (Addgene 42230). The sgRNA oligonucleotides 
targeting the AAVS1 region were inserted into the plasmid downstream of the U6 
promoter using restriction sites AgeI and EcorI.  
Supercharged eGFP-Trail DNA sequences were constructed by using site-directed 
mutagenesis (Agilent) PCR. Indicated amino acids of the wildtype eGFP sequence were 
replace with neutral or positively charged amino acids. Protein surface charge was 
calculated by summing up the total charge of the eGFP sequence based on the predicted 
charge of the amino acids in the sequence. All plasmid constructs were verified by 
sequencing.    
CRISPR/CAS9 Knock-In of eGFP-TRAIL  
2x106 PLB-985 cells were nucleofected (AMAXA Cell Nucleofector Kit V and Amaxa 
Nucleofactor II, program C-023) With 20  g of pAAVS1-eGFP-TRAIL and 20  g of 
pX330-U6-AAVS1. Immediately after nucleofection 500  l of medium was added to 
the cuvette and the cells incubated at room temperature for 10 min. Then the cells were 
cultured for 48 h. After 48 h, GFP-expressing cells were selected with culture medium 
supplemented with 2  g/mL Puromycin. 
Chemical and Antibodies 
TACS® Annexin V Kit (Gaithersburg, MD, USA) was used for assaying cell apoptosis. 
Reagents for SEM were obtained from Electron Microscopy Sciences (Hatfield, PA, 
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USA): glutaraldehyde, osmium tetroxide and uranyl acetate. Antibodies for human 
TRAIL were purchased from Biolegend (San Diego, CA, USA). Primary antibodies for 
human TRAIL and β-actin were obtained from PeproTech (Rocky Hill, NJ, USA) and 
Santa Cruz Biotech (Santa Cruz, CA, USA). HRP-conjugated anti-mouse and anti-
rabbit antibodies were obtained from Santa Cruz Biotech. IL-8 human Elisa Kits were 
purchased from ThermoFisher. 
 
 
 
 
 
 
 
 
 
 
 
 
  29 
 
Figure 2.1: Neutrophils undergo spontaneous NETosis in the presence of tumor cells. (a) 
cfDNA plasma DNA level of normal donors (ND) and cancer patients (PAT). (b) Confocal 
images of neutrophils underwent NETosis in conditioned media. (CTL) – control group, 
COLO-205 and SW-620 are condition media collected after 48 h from these indicated 
cell lines. (c) NETosis level of neutrophils after culturing in conditioned media for 24 h. 
(d-e) Extracellular tumor-derived IL-8 levels in conditioned media. Reparixin 
concentration (20  g/mL).   
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Figure 2.2: Engineered neutrophils express supercharged eGFP-TRAIL on NETs during 
NETosis (a) Schematic of the insertion site, AAVS1, on chromosome 19. Cartoon 
representation of eGFP-TRAIL chimeric protein. Surface charge of eGFP ranging from 
-4 to +36 (Red - negative charge, Blue - positive charge. (b) DNA sequencing result of 
genomic DNA isolated from cells positive for eGFP-TRAIL. (c) relative mRNA level of 
endogenous (enTRAIL) and exogenous (exTRAIL) TRAIL levels. (d) Flow cytometry of 
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cells expressing eGFP-TRAIL 24 h after nucleofection. (e) Confocal images of NETs 
decorated with eGFP-TRAIL (Blue – DAPI stain, Green – eGFP-TRAIL. (f) Immuno-gold 
SEM images of neutrophils expressing eGFP-decorated NETs (White arrows – eGFP-
TRAIL).  
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Figure 2.3: Supercharged eGFP-TRAIL expressing neutrophils trap and destroy tumor 
cells during NETosis (a) Representative flow cytometry result of COLO-205 cells co-
cultured with eGFP-TRAIL expressing neutrophils for 24 h and stained for apoptosis and 
necrosis using Annexin V and Propodium Iodide, respectively. (b) Cell viability 
quantification of indicated cancer cell lines co-cultured with wildtype neutrophils or cells 
positive for eGFP-TRAIL (Tf). (c) Immuno-gold SEM images of indicated cancer cells 
co-cultured with neutrophils.  
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CHAPTER 3 
Effect of Extracellular pH on Selectin Adhesion: Theory and Experiment 
This chapter were published in the Biophysical Journal (136). 
3.1 ABSTRACT  
Selectins mediate circulatory leukocyte trafficking to sites of inflammation and trauma, 
and the extracellular microenvironments at these sites often become acidic. In this study, 
we investigated the influence of slightly acidic pH on the binding dynamics of selectins 
(P-, L-, and E-selectin) to P-selectin glycoprotein ligand-1 (PSGL-1) via computational 
modeling (molecular dynamics) and experimental rolling assays under shear in vitro. The 
P-selectin/PSGL-1 binding is strengthened at acidic pH, as evidenced by the formation 
of a new hydrogen bond (seen computationally) and the observed decrease in the rolling 
velocities of model cells. In the case of L-selectin/PSGL-1 binding dynamics, the binding 
strength and frequency increase at acidic pH, as indicated by the greater cell-rolling flux 
of neutrophils and slower rolling velocities of L-selectin-coated microspheres, 
respectively. The cell flux is most likely due to an increased population of L-selectin in 
the high-affinity conformation as pH decreases, whereas the velocities are due to 
increased L-selectin/PSGL-1 contacts. In contrast to P- and L-selectin, the E-
selectin/PSGL-1 binding does not exhibit significant changes at acidic pH levels, as 
shown both experimentally and computationally.  
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3.2 INTRODUCTION  
The localization of circulating leukocytes to sites of injury or inflammation is a multistep 
adhesion cascade (137, 138) involving a), the initial tethering and rolling of leukocytes 
along the vasculature wall; b), integrin-mediated firm adhesion; and c), the extravasation 
of cells into tissues (139). Selectins (P-, L-, and E-selectin) are membrane adhesion 
molecules that facilitate the initial tethering and rolling of leukocytes. Although selectin-
mediated cell rolling is ubiquitously observed for leukocytes, accumulating evidence 
suggests that circulating tumor cells (CTCs) also exhibit selectin-mediated rolling (140, 
141).  
Selectins are differentially expressed on many cell types. P-selectin is stored in the a-
granules of platelets and the Weibel-Palade bodies of endothelial cells, and upon 
activation of the endothelial cells is rapidly transported to the surface (142, 143). E-
selectin expression is limited to the endothelial lining (144), and in addition to mediating 
leukocyte rolling during inflammation, it has also been shown to assist human CD34þ 
hematopoietic cell homing to the bone marrow (145). Whereas P- and E-selectin are 
endothelial selectins, L-selectin is expressed on most circulating leukocytes, with the 
exception of several subpopulations of memory cells (146). The presenting architectures 
of selectins are highly conserved. Their structures consist of a C-type lectin domain at the 
N-terminus, an epidermal growth factor (EGF)-like module, two to nine short consensus 
repeats, a transmembrane region, and a cytoplasmic tail (147). Selectin ligands consist of 
a structurally diverse array of surface glycoproteins (e.g., GlyCAM-1, CLA, HCELL, and 
PSGL-1) (148–150). These ligands require post-translational N- and/or O-linked 
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glycosylation of their backbone with a tetrasaccharide carbohydrate called sialyl Lewis 
X (sLeX) to gain selectin-binding activity. sLeX and its derivative sLeA are the most 
basic binding determinants for all three selectins. In this study, we focus on 
selectin/PSGL-1 binding because PSGL-1, a glycoprotein heavily decorated with sLeX, 
is a common vascular selectin ligand that can readily bind to all three selectins.  
The physiologic pH level in extracellular microenvironments can significantly decrease 
due to various pathological and physiological phenomena. For example, anaerobic lactate 
buildup and inadequate extraction of metabolites during prolonged ischemia can decrease 
the extracellular pH level, a condition known as acidosis (151, 152). Studies have shown 
that acidosis occurs in the early stages of wound healing (153, 154), which also involves 
periods of elevated leukocyte and platelet recruitment. Serrano et al. (155) showed that 
under acidic conditions, neutrophil adhesion to the vascular endothelium is enhanced. 
Acidic conditions also promote angiogenesis of injured tissues (156). Further- more, 
tumor microenvironments are often acidic, with pH levels as low as 6.2 (157, 158). In 
addition, because the recruitment of leukocytes to targeted tissues is selectin mediated, 
these observations suggest that acidic pH might alter selectin/ligand-binding mechanics, 
resulting in a change in cell binding dynamics compared with the homeostasis pH level 
of 7.4.  
In this study, we investigated the influence of acidic extra- cellular pH on P-, L-, and E-
selectin interactions with PSGL-1 and sLex. We used molecular dynamics (MD) and 
steered MD (SMD) to predict changes in adhesion characteristics while performing cell-
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rolling assays with selectin- coated capillary tubing to characterize the effects of pH on 
cell rolling and adhesion in vitro.  
3.3 MATERIALS AND METHODS  
MD  
The lectin and EGF crystal structures of P-selectin bound to PSGL-1 (1G1S (159)), E-
selectin (1G1T (159)), and L-selectin (3CFW) were obtained from the Protein Data Bank 
for use as starting atomic coordinates. Free-dynamics and SMD simulations were 
performed using the YASARA (http://yasara.org) package of MD programs with the 
YAMBER3 self-parameterizing force field (160), and therefore no external force field 
parameters were specified. For all types of simulations, the temperature and pressure were 
held constant at 300 K and 1 atm, respectively. Periodic boundary conditions, the particle 
mesh Ewald method for electrostatic interactions (161), and the recommended 7.86 A ̊ 
force cutoff for long-range interactions were also used.  
For equilibration simulations, each selectin was individually solvated in a water box and 
neutralized by adding Ca2þ and Cl ions to a concentration of ~50 mM calcium. To allow 
for free protein rotation, the water boxes were defined as cubes with lengths measuring 
~10 A ̊ away from the two farthest atoms in each complex. The P-selectin (subunit A), E-
selectin, and L-selectin water cube lengths were ~100 A ̊ , 80 A ̊ , and 80 A ̊ , respectively. 
The water boxes were allowed to adjust slightly to constrain the water density to 0.997 
g/L. The conformational stresses were then removed via short steepest-descent 
minimizations followed by simulated annealing until sufficient convergences were 
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reached. To simulate the effect of pH, changes in pKa values for the amino acids were 
computed by the fast empirical pKa prediction method as implemented by YASARA 
(162). At the physiologically neutral pH condition, amino acids with pKa values R 7.4 
were protonated, and at physiologically relevant acidic pH conditions, amino acids with 
pKa values R 6.2 were protonated. Free-dynamics simulations were then run for each 
selectin in both neutral and acidic conditions for 10 ns time periods.  
Predicted structures of PSGL-1 bound to L- and E-selectin were obtained by aligning the 
L-selectin (3CFW) and E-selectin (1G1T) crystal structures on the P-selectin/PSGL-1 
complex (1G1S, subunit a) via the MUSTANG algorithm (163). This approach is similar 
to that used in previous studies of L-selectin/PSGL-1 binding dynamics (164, 165). After 
the structures were overlaid, free-dynamics simulations were run for the L-
selectin/PSGL-1 and E-selectin/PSGL-1 complexes at physiologically neutral pH 
conditions and the above MD parameters for 10 ns time periods. The equilibrated 
complex structures were then run for another 10 ns after the protonation of relevant amino 
acids in neutral and acidic conditions.  
Following previous SMD studies on the P-selectin/PSGL-1 complex (166), the Gly-147 
residue was held frozen as the Ca atom of the Pro-18 residue was pulled through a spring 
with a spring constant of 70 pN/A ̊ and a speed of 5 A ̊ /ns. To reduce the computational 
cost of these simulations, the simulation cells were changed to a water box of 140  50  60 
A ̊ 3 and were also neutralized by adding CaCl2 to a concentration of ~50 mM Ca. To 
further prevent the EGF domain from unfolding during SMD simulations with the 
YAMBER3 force field, the Gln-130 residue was also held frozen. SMD simulations were 
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run until the PSGL-1 completely dissociated from the P-selectin binding site. The same 
conditions were also used for L-selectin/PSGL-1 SMD simulations, except that the Gly-
129 residue of the EGF domain was held frozen instead of residue 130. All SMD 
simulations were run in triplicate to verify the dissociation times.  
Reagents and antibodies  
RPMI 1640 cell culture media, fetal bovine serum (FBS), penicillin-streptomycin, 
phosphate-buffered saline (PBS), and Hank’s balanced salt solution (HBSS) were 
purchased from Invitrogen (Grand Island, NY). Recombinant human P-, L-, and E-
selectin/IgG chimera were purchased from R&D Systems (Minneapolis, MN).  
Cell lines and cell culture  
The acute myeloid leukemic KG1a cell line (ATCC number CCL-264.1) was purchased 
from ATCC (Manassas, VA) and cultured in RPMI 1640 media supplemented with 2 mM 
L-glutamine, 25 mM HEPES, 10% (v/v) FBS, and 100 U/mL penicillin-streptomycin at 
37C and 5% CO2.  
Neutrophil isolation  
Human peripheral blood was collected from healthy adult donors after they provided 
informed consent. Neutrophils were isolated using 1-Step Polymorphs (Accurate 
Chemical and Scientific; Westbury, NY) according to a previously described protocol 
(167). Isolated neutrophils were resus- pended at a concentration of 106 cells/mL in 
HBSS buffer supplemented with 0.5% (wt/vol) human serum albumin, 10 mmol/L 
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HEPES, and 2 mmol/L CaCl2. In specified experiments, 35 mmol of TAPI-0 was added 
to mitigate mechanical shedding of L-selectin (168). Experiments involving neutrophils 
were completed within 6 h after the neutrophils were extracted from the donor.  
Microtube functionalization  
Micro-Renathane (MRE) tubes (300 mm i.d. and 50 cm long; Braintree Scientific, 
Braintree, MA) were sterilized with 75% ethanol for 15 min. After three washes with PBS 
(Caþþ and Mnþþ free), the microtubes were incubated with Protein G (2 mg/ml PBS) for 
1 h. Next, the inner luminal surface was functionalized with recombinant human P-
selectin, E-selectin, or PSGL-1 at specified concentrations for 2 h. The microtubes were 
then incubated with dry milk powder (5% w/v) in PBS for 1 h to prevent nonspecific 
adhesion (169). For control experiments, microtubes were prepared as indicated above 
except that the adhesion molecule was replaced with BSA.  
Microsphere functionalization  
SuperAvidin-coated microspheres (CP01N/10216) and Protein-A-coated microspheres 
(CP02N/10279) were purchased from Bangs Laboratories (Fishers, IN). Microspheres 
were washed three times with PBS buffer. Next, the microspheres were incubated with 
adhesion proteins at specified concentrations for 1 h with gentle mixing every 15 min. 
Finally, the micro- spheres were washed twice and resuspended in buffer (1  106 micro- 
spheres/ml) at varying pH levels.  
Microtube flow experiment  
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Cells or microspheres suspended in flow buffer (PBS supplemented with 2 mmol Caþþ) 
at varying pH were perfused through the microtubes using a syringe pump at specified 
wall shear stresses. Videos were recorded for 1 min at random locations along the length 
of the microtube after 5 min of perfusion.  
Data acquisition  
Videos of the rolling cells were captured using a microscope-linked Hitachi CCD camera 
KP-M1AN (Hitachi, Japan) and a Sony DVD Recorder DVO- 1000MD (San Diego, CA). 
Rolling velocity was determined using ImageJ (U.S. National Institutes of Health, 
Bethesda, MD). Rolling cells were defined as any cell translating along the tube surface 
for >2 s at a velocity < 50% of the free stream velocity of a noninteracting cell near the 
tube wall. Rolling flux was determined by counting the number of cells that entered the 
field of view over a period of 1 min.  
Statistical analysis  
Rolling velocity and rolling flux were plotted and analyzed using Prism (GraphPad 
Software, San Diego, CA). Two-tailed unpaired t-tests were used to analyze results.  
3.4 RESULTS AND DISCUSSION  
P-selectin/PSGL-1 adhesion at acidic pH—SMD analysis  
Figure 3.1 depicts the equilibrated P-selectin/PSGL-1 complex structures at 
physiologically neutral pH (A) and acidic pH (B), and the histidine pKa values for P-
selectin bound (pKa*) and unbound (pKa) from PSGL-1 are shown in Table 3.1. When 
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P-selectin was not bound to PSGL-1, the pre- dicted histidine pKa values were <5.8, 
suggesting that no significant change in histidine protonation states or protein 
conformation occurs in slightly acidic pH environments. On the other hand, when P-
selectin was bound to PSGL-1, the predicted H114 pKa value increased from 5.0 to 7.1, 
thus allowing H114 to be protonated in slightly acidic environments. As a result, a 
hydrogen bond between H114 and Y7 (on PSGL-1) was formed after H114 protonation, 
which would suggest an increase in binding energy and possibly longer interaction 
lifetimes.  
To examine the effect of H114 protonation on the binding lifetime of the P-
selectin/PSGL-1 complex, we used SMD to manually dissociate PSGL-1 from P-selectin. 
Representative SMD force versus time graphs are shown in Figure 3.2 to illustrate 
variations between neutral and acidic environments. Interestingly, there was a remarkable 
difference in the dissociation dynamics depending on the protonation state of H114. At 
the start of the simulation (Figure 3.1), the P-selectin/PSGL-1 complex conformations 
were nearly identical where clear H114/Y7 and R85/Y10 contacts were present, as 
suggested by Somers et al. (159). However, after 6 ns in neutral conditions, R85 had 
already dissociated from Y10 to form a hydrogen bond to sLeX (Figure 3.2b), whereas 
in acidic conditions the R85/Y10 contact was preserved (Figure 3.2d), most likely due to 
the increased inter-action energy from the hydrogen-bonded H114/Y7 contact. Moreover, 
Y5 was hydrogen-bonded to both K8 and the P-selectin backbone, resulting in a total of 
four contacts in acidic conditions, compared with two contacts in neutral conditions. As 
PSGL-1 was pulled away from P-selectin in neutral conditions, the Y5 and Y7 amino 
acids underwent several sliding-rebinding events involving K8, K112, and the P-selectin 
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backbone, resulting in a force plateau from 8.5 to 10.5 ns. Subsequent to the numerous 
sliding-rebinding events, Y5 was pulled too far to contact P-selectin significantly (Figure 
3.2c). In contrast, at ~9 ns in acidic conditions, there was a rupture of all contacts (except 
for coordination bonding), signified by a dramatic decrease in the pulling force. The R85 
and Y7 contacts were then bonded to sLeX and H114, respectively, while Y5 was kept 
within the binding range of K8 and K112 (Figure 3.2e). On average, the protonation of 
H114 increased the binding lifetime by >1 ns, and therefore cells expressing PSGL-1 
were predicted to roll more slowly at slightly acidic pH than at physiologically neutral 
pH on P-selectin surfaces.  
P-selectin/PSGL-1 adhesion at acidic pH—experimental rolling analysis  
To further substantiate our SMD results, we investigated P-selectin/PSGL-1 complex 
binding dynamics in acidic environments in vitro by perfusing KG1a cell suspensions 
through P-selectin-coated microtubes at varying pH levels (6.2–7.4) with a flow rate of 
0.111 ml/min, an equivalent shear stress of 7 dyn/cm2 (Figure 3.3a). Cell rolling was con- 
firmed to be specifically mediated by P-selectin/ PSGL-1 binding, because all interactions 
were abrogated when cells were perfused in Ca2þ-free buffer containing 5 mM of EDTA 
(data not shown). As the buffer pH level decreased from 7.4 to 6.8, KG1a cells rolled 
more slowly, with the average rolling velocity reaching a minimum of 4.25 5 0.21 mm/s 
at pH 6.8, suggesting longer P-selectin/PSGL-1 interaction lifetimes at slightly acidic pH 
levels. Conversely, pH levels below 6.8 decreased the binding interaction life- time of P-
selectin to PSGL-1, which was manifested by an increase in rolling velocity. Rolling-
assay experiments were also performed with PSGL-1 coated microspheres as shown in 
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Figure 3.3b. The microspheres exhibited rolling characteristics similar to those of KG1a 
cells: the average rolling velocity decreased at slightly acidic pH, with a minimum at pH 
6.6, and increased from the minimum at pH levels below 6.6. This increase in rolling 
velocity may be a consequence of the on-rate kinetics. Microspheres that were 
functionalized with carbohydrate sLeX (effectively eliminating the putative PSGL-1 
backbone responsible for hydrogen binding) did not exhibit enhanced binding lifetime in 
slightly acidic environments (Figure 3.3 C).  
Circulating myeloid cells express PSGL-1 on their surfaces, which serve as a 
counterreceptor for P-selectin (170). As previously mentioned, P-selectin/ligand binding 
facilitates the tethering and eventual rolling of myeloid cells on the activated endothelial 
lining during physiological events such as injury to the vessel wall and inflammation. 
These phenomena are often coupled with a decrease in pH level in the microenvironment 
where adhesion occurs (171). The results of both the computational and experimental 
studies presented here suggest that in slightly acidic environments, the binding of the P-
selectin/PSGL-1 com- plex is enhanced due to the formation of a hydrogen bond between 
the protonated H114 (P-selectin) and Y7 (PSGL-1) residues. Our findings suggest that 
during inflammation, a drop in pH may have a contributory effect on recruiting circulating 
myeloid cells by increasing the binding strength and lifetime between P-selectin to PSGL-
1, which slows cell rolling velocities at and around the target site.  
L-selectin/PSGL-1 adhesion at acidic pH—MD analysis  
Given the good agreement between theory and experiment for P-selectin, a similar 
computational analysis was per- formed for L-selectin, as shown in Figures 3.4 and 3.5. 
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L-selectin contains three histidine residues that potentially can be protonated. The H4 and 
H130 residues had predicted pKa values of 6.9 and 6.8 (Table 3.2), respectively, when 
not bound to PSGL-1, and therefore likely change protonation states in slightly acidic 
conditions. The main effect of protonating these two residues in acidic conditions was the 
dissociation of the hydrogen bond between the N138 residue (of the EGF domain) and 
the lectin domain. This hydrogen bond is important, because Phan et al. (172) found that 
a single point mutation of N138 to glycine increased cell flux, decreased cell rolling 
velocities, and increased the duration of cell-tethering events. They suggested that these 
changes were due to a greater L-selectin population in the extended (high-affinity) 
conformation.  
The predicted L-selectin/PSGL-1 complex showed an increase of the H110 pKa value 
from 4.6 (unbound) to 6.5 (bound) and was also expected to be protonated in slightly 
acidic conditions. The protonation of H110 dramatically changed the PSGL-1 
conformation, yielding a stacking interaction between H110 and L13, and increased the 
likelihood of hydrogen bonding between Y7 and the L-selectin backbone (Figure 3.5). 
SMD simulations demonstrated that the protonation of H110 increased the L-
selectin/PSGL-1 binding lifetime by >1.5 ns, as shown by the representative SMD force 
versus time graphs in Figure 3.5. A similar result was discovered via the mutation of 
A108 of L-selectin (an amino acid neighboring H110) to histidine, where the mutation 
was proposed to increase the stacking interactions of L-se- lectin and PSGL-1, resulting 
in an increased binding interaction (164). Therefore, an acidic pH environment should 
produce considerable changes in the rolling profiles of cells expressing L-selectin when 
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perfused over PSGL-1-coated surfaces via a change in selectin conformation and an 
increased selectin/PSGL-1 binding interaction.  
L-selectin/PSGL-1 adhesion at acidic pH— experimental rolling analysis  
Rolling-assay experiments with isolated human neutrophils perfused through PSGL-1-
coated microtubes showed that the neutrophils maintained a statistically constant rolling 
profile at pH levels ranging from 7.4 down to 6.6, but steadily increased as the pH level 
became more acidic than 6.6 (Figure 3.6a). Interestingly, pH had an effect on the number 
of neutrophils that adhered and rolled on the PSGL-1-coated surface, causing the cell flux 
to increase in more acidic conditions over a range of shear stresses (Figure 3.6 c). This 
suggests that slightly acidic pH may increase the binding frequency of L-selectin to 
PSGL-1, as manifested by a higher rolling flux at lower pH. Rolling-assay experiments 
using L-selectin-coated micro- spheres perfused over PSGL-1-coated surfaces were also 
conducted (Figure 3.6b). Interestingly, the microspheres rolled more slowly at pH 7.2 
than at 7.4 and remained at this depressed velocity at pH levels as low as 6.4 before they 
began to increase to higher velocities at pH levels below 6.4, indicating stronger L-
selectin/PSGL-1 interactions at slightly acidic pH. In contrast to a uniformly coated 
microbead, the surface of neutrophils primarily express L-selectin on the tips of microvilli 
(167, 173). Neutrophils use these L-selectin-decorated microvilli to attach to the targeted 
surface expressing L-selectin receptors. Furthermore, neutrophils can passively deform 
and modulate the number of microvilli attached to the substrate in accordance with 
external stimuli to allow maximum stability—a mechanism that is unavailable to 
microspheres (174, 175). These observations may explain why the effect of pH on L-
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selectin/ PSGL-1 interactions are more pronounced on rolling micro- spheres than on 
neutrophils. However, the rolling flux for the microspheres exhibited the same behavior 
as neutro- phils: at lower pH conditions, a greater flux of rolling micro- spheres was 
observed on PSGL-1-coated surfaces (data not shown).  
E-selectin/PSGL-1 adhesion at acidic pH—MD analysis  
To complete our study of selectins, we performed a pKa analysis of E-selectin as shown 
in Figure 3.7. In this case, only two histidine residues were present, where the H25 
predicted pKa was 6.8 (Table 3.3) and could change protonation states in slightly acidic 
conditions. However, H25 is not near the calcium ion and was not observed to increase 
amino acid contacts between E-selectin and PSGL-1 (structure not shown). Moreover, 
the N138 residue did not contact the lectin domain in either neutral or acidic conditions. 
Hence, pH is not expected to affect the binding strength or the binding affinity of PSGL-
1 to E-selectin, and no significant change in rolling profiles is expected for cells 
expressing PSGL-1 when perfused over E-selectin-coated surfaces.  
E-selectin/PSGL-1 adhesion at acidic pH— experimental rolling analysis  
Figure 3.8a displays the rolling velocity profile for KG1a cells perfused through E-
selectin-coated microtubes, where only a steady rise in rolling velocities was observed as 
the pH level became more acidic. However, the PSGL-1-coated microspheres did not 
demonstrate any significant change in rolling velocity at any pH level (Figure 3.8b). 
These data, along with the computational predictions, indicate that the pH range 
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investigated in this study does not significantly affect E-selectin/PSGL-1 binding 
dynamics.  
3.5 CONCLUSIONS  
Acidic extracellular pH does indeed alter the adhesion dynamics of certain selectins to 
PSGL-1, which causes differential rolling and adhesion characteristics of cells dependent 
on selectin-mediated rolling. P-selectin/PSGL-1 binding was enhanced at slightly acidic 
pH due to the formation of a new hydrogen bond between H114 (P-selectin) and Y7 
(PSGL-1). As a result, the P-selectin/PSGL-1 binding lifetime increased, and, 
correspondingly, cell roll- ing velocities on P-selectin-coated surfaces were ex- 
perimentally shown to decrease. When cells expressing L-selectin were perfused through 
PSGL-1-coated micro- tubes, cell flux increased at slightly acidic pH, whereas rolling 
velocities remained unchanged. The cell flux is primarily due to the altered structure of 
L-selectin at acidic pH, where the hydrogen bond between residue N138 (EGF domain) 
and the lectin-binding domain is dissociated as a result of protonating the H4 and H130 
residues. The dissociation of this hydrogen bond allows L-selectin to assume a more 
flexible conformation (high affinity) that results in improved frequency of binding to 
PSGL-1. On the other hand, residue H110 is also predicted to be protonated when bound 
to L-selectin in acidic conditions that increase contacts and strengthen the binding 
interaction. We only observed this effect (i.e., slower rolling velocity) when we 
eliminated cellular effects by using L-selectin-coated micro- spheres. A previous study 
by Serrano et al. (155) also showed that neutrophil recruitment is enhanced in acidic 
conditions due to the upregulation of CD18 by the neutrophils. In this study, we showed 
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that before firm adhesion facilitated by the CD18/ICAM-1 interaction occurs, acidic pH 
also enhances neutrophil recruitment in the initial step of the adhesion cascade through 
the mediation of L-selectin/PSGL-1 binding dynamics. In contrast to P- and L-selectin, 
E-selectin/ PSGL-1 binding was not significantly affected by acidic pH. In conclusion, 
both theoretical predictions and experimental observations indicate that the extracellular 
pH level modulates selectin adhesion under flow. Thus, the extracellular pH level may 
serve as an external signaling stimulus for leukocytes trafficking during the inflammatory 
response. These results further suggest an additional axis that can be used to control 
applications such as the selectin-based isolation of CTCs and hematopoietic stem cells 
(169, 176).  
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Figure 3.1: (A) Equilibrated PSGL-1 (magenta) and sLeX (orange) structures bound to 
P-selectin (gray) at physiologically neutral pH. (B) Equilibrated P-selectin/PSGL-1 
structure at physiologically acidic pH, where the H114/Y7 contact forms a hydrogen 
bond. All hydrogens except for those on the imidazoles of histidines are omitted for 
clarity, and the yellow sphere is the calcium ion. All figures available online in color. 
Adapted from T. Cao et al. Biophys. J. 104, 292–299 (2013).Statistical analysis
Rolling velocity and rolling flux were plotted and analyzed using Prism
(GraphPad Software, San Diego, CA). Two-tailed unpaired t-tests were
used to analyze results.
RESULTS AND DISCUSSION
P-selectin/PSGL-1 adhesion at acidic pH—SMD
analysis
Fig. 1 depicts the equilibrated P-selectin/PSGL-1 complex
structures at physiologically neutral pH (A) and acidic pH
(B), and the histidine pKa values for P-selectin bound
(pKa*) and unbound (pKa) from PSGL-1 are shown in
Table 1. When P-selectin was not bound to PSGL-1, the pre-
dicted histidine pKa values were <5.8, suggesting that no
significant change in histidine protonation states or protein
conformation occurs in slightly acidic pH environments.
On the other hand, when P-selectin was bound to PSGL-1,
the predicted H114 pKa value increased from 5.0 to 7.1,
thus allowing H114 to be protonated in slightly acidic envi-
ronments. As a result, a hydrogen bond between H114 and
Y7 (on PSGL-1) was formed after H114 protonation, which
would suggest an increase in binding energy and possibly
longer interaction lifetimes.
To examine the effect of H114 protonation on the bind-
ing lifetime of the P-selectin/PSGL-1 complex, we used
SMD to manually dissociate PSGL-1 from P-selectin.
Representative SMD force versus time graphs are shown
in Fig. 2 to illustrate variations between neutral and acidic
FIGURE 1 (A) Equilibrated PSGL-1 (magenta) and sLeX (orange) struc-
tures bound to P-selectin (gray) at physiologically neutral pH. (B) Equili-
brated P-selectin/PSGL-1 structure at physiologically acidic pH, where
the H114/Y7 contact forms a hydrogen bond. All hydrogens except for
those on the imidazoles of histidines are omitted for clarity, and the yellow
sphere is the calcium ion. All figures available online in color.
TABLE 1 Predicted histidine pKa values for unbound
P-selectin (left) and P-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 5.0 6.1
H108 5.8 5.9
H114 5.0 7.1
FIGURE 2 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from P-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time point 1 represents the rupture of
all amino acid contacts, except for coordination bonding, in the acidic
case. Time point 2 represents a long force plateau in the neutral case, where
several sliding and rebinding events occur. Time point 3 represents the
complete rupture of all bonds, leading to the dissociation of PSGL-1
from P-selectin in both conditions. (B) Representative P-selectin/PSGL-1
structure in neutral conditions for time periods < ~6 ns, where R85 forms
a hydrogen bond with sLeX, and Y5 forms a hydrogen bond with the back-
bone structure of P-selectin. (C) Representative structure in neutral condi-
tions for a time period > ~10 ns, where Y5 has no contacts and Y7 forms
a contact with the backbone structure of P-selectin. (D) Representative
structure in acidic conditions for time periods < ~6 ns, where Y5 has
two hydrogen bonds with K8 and the backbone structure of P-selectin,
Y7 forms a hydrogen bond to H114, and Y10 is hydrogen bound to R85.
(E) Representative structure in acidic conditions for time periods >
~10 ns, where Y7 is still hydrogen bound to H114 and forms a hydrogen
bond with the P-selectin backbone structure, and R85 is now hydrogen
bound to sLeX.
Biophysical Journal 104(2) 292–299
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Figure 3.2: (A) Representative SMD force versus time graphs depicting the dissociation 
of PSGL-1 from P-selectin in physiologically neutral (red) and acidic (blue) conditions. 
Time point 1 represents the rupture of all amino acid contacts, except for coordination 
bonding, in the acidic case. Time point 2 represents a long force plateau in the neutral 
Statistical analysis
Rolling velocity and rolling flux were plotted and analyzed using Prism
(GraphPad Software, San Diego, CA). Two-tailed unpaired t-tests were
used to analyze results.
RESULTS AND DISCUSSION
P-selectin/PSGL-1 adhesion at acidic pH—SMD
analysis
Fig. 1 depicts the equilibrated P-selectin/PSGL-1 complex
structures at physiologically neutral pH (A) and acidic pH
(B), and the histidine pKa values for P-selectin bound
(pKa*) and unbound (pKa) from PSGL-1 are shown in
Table 1. When P-selectin was not bound to PSGL-1, the pre-
dicted histidine pKa values were <5.8, suggesting that no
significant change in histidine protonation states or protein
conformation occurs in slightly acidic pH environments.
On the other hand, when P-selectin was bound to PSGL-1,
the predicted H114 pKa value increased from 5.0 to 7.1,
thus allowing H114 to be protonated in slightly acidic envi-
ronments. As a result, a hydrogen bond between H114 and
Y7 (on PSGL-1) was formed after H114 protonation, which
would suggest an increase in binding energy and possibly
longer interaction lifetimes.
To examine the effect of H114 protonation on the bind-
ing lifetime of the P-selectin/PSGL-1 complex, we used
SMD to manually dissociate PSGL-1 from P-selectin.
Representative SMD force versus time graphs are shown
in Fig. 2 to illustrate variations between neutral and acidic
FIGURE 1 (A) Equilibrated PSGL-1 (magenta) and sLeX (orange) struc-
tures bound to P-selectin (gray) at physiologically neutral pH. (B) Equili-
brated P-selectin/PSGL-1 structure at physiologically acidic pH, where
the H114/Y7 contact forms a hydrogen bond. All hydrogens except for
those on the imidazoles of histidines are omitted for clarity, and the yellow
sphere is the calcium ion. All figures available online in color.
TABLE 1 Predicted histidine pKa values for unbound
P-selectin (left) and P-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 5.0 6.1
H108 5.8 5.9
H114 5.0 7.1
FIGURE 2 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from P-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time point 1 represents the rupture of
all amino acid contacts, except for coordination bonding, in the acidic
case. Time point 2 represents a long force plateau in the neutral case, where
several sliding and rebinding even s occur. Time point 3 represen the
complete rupture of all bonds, leading to the dissociation of PSGL-1
fr m P-selectin in both conditions. (B) Representative P-selecti /PSGL-1
structure in neutral conditions for time periods < ~6 ns, where R85 forms
a hydrogen bond with sLeX, and Y5 forms a hydrogen bond with the back-
bone structure of P-selectin. (C) Representative structure in neutral condi-
tions for a time period > ~10 ns, where Y5 has no contacts and Y7 forms
a contact with the backbone structure of P-selectin. (D) Representative
structure in acidic conditions for time periods < ~6 ns, where Y5 has
two hydrogen bonds with K8 and the backbone structure of P-selectin,
Y7 forms a hydrogen bond to H114, and Y10 is hydrogen bound to R85.
(E) Representative structure in acidic conditions for time periods >
~10 ns, where Y7 is still hydrogen bound to H114 and forms a hydrogen
bond with the P-selectin backbone structure, and R85 is now hydrogen
bound to sLeX.
Biophysical Journal 104(2) 292–299
294 Cao et al.
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case, where several sliding and rebinding events occur. Time point 3 represents the 
complete rupture of all bonds, leading to the dissociation of PSGL-1 from P-selectin in 
both conditions. (B) Representative P-selectin/PSGL-1 structure in neutral conditions for 
time periods < ~6 ns, where R85 forms a hydrogen bond with sLeX, and Y5 forms a 
hydrogen bond with the back- bone structure of P-selectin. (C) Representative structure 
in neutral condi- tions for a time period > ~10 ns, where Y5 has no contacts and Y7 forms 
a contact with the backbone structure of P-selectin. (D) Representative structure in acidic 
conditions for time periods < ~6 ns, where Y5 has two hydrogen bonds with K8 and the 
backbone structure of P-selectin, Y7 forms a hydrogen bond to H114, and Y10 is 
hydrogen bound to R85. (E) Representative structure in acidic conditions for time periods 
> ~10 ns, where Y7 is still hydrogen bound to H114 and forms a hydrogen bond with the 
P-selectin backbone structure, and R85 is now hydrogen bound to sLe.X Adapted from T. 
Cao et al. Biophys. J. 104, 292–299 (2013). 
 
 
 
 
  52 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis
Rolling velocity and rolling flux were plotted and analyzed using Prism
(GraphPad Software, San Diego, CA). Two-tailed unpaired t-tests were
used to analyze results.
RESULTS AND DISCUSSION
P-selectin/PSGL-1 adhesion at acidic pH—SMD
analysis
Fig. 1 depicts the equilibrated P-selectin/PSGL-1 complex
structures at physiologically neutral pH (A) and acidic pH
(B), and the histidine pKa values for P-selectin bound
(pKa*) and unbound (pKa) from PSGL-1 are shown in
Table 1. When P-selectin was not bound to PSGL-1, the pre-
dicted histidine pKa values were <5.8, suggesting that no
significant change in histidine protonation states or protein
conformation occurs in slightly acidic pH environments.
On the other hand, when P-selectin was bound to PSGL-1,
the predicted H114 pKa value increased from 5.0 to 7.1,
thus allowing H114 to be protonated in slightly acidic envi-
ronments. As a result, a hydrogen bond between H114 and
Y7 (on PSGL-1) was formed after H114 protonation, which
would suggest an increase in binding energy and possibly
longer interaction lifetimes.
To examine the effect of H114 protonation on the bind-
ing lifetime of the P-selectin/PSGL-1 complex, we used
SMD to manually dissociate PSGL-1 from P-selectin.
Representative SMD force versus time graphs are shown
in Fig. 2 to illustrate variations between neutral and acidic
FIGURE 1 (A) Equilibrated PSGL-1 (magenta) and sLeX (orange) struc-
tures bound to P-selectin (gray) at physiologically neutral pH. (B) Equili-
brated P-selectin/PSGL-1 structure at physiologically acidic pH, where
the H114/Y7 contact forms a hydrogen bond. All hydrogens except for
those on the imidazoles of histidines are omitted for clarity, and the yellow
sphere is the calcium ion. All figures available online in color.
TABLE 1 Predicted histidine pKa values for unbound
P-selectin (left) and P-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 5.0 6.1
H108 5.8 5.9
H114 5.0 7.1
FIGURE 2 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from P-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time point 1 represents the rupture of
all amino acid contacts, except for coordination bonding, in the acidic
case. Time point 2 represents a long force plateau in the neutral case, where
several sliding and rebinding events occur. Time point 3 represents the
complete rupture of all bonds, leading to the dissociation of PSGL-1
from P-selectin in both conditions. (B) Representative P-selectin/PSGL-1
structure in neutral conditions for time periods < ~6 ns, where R85 forms
a hydrogen bond with sLeX, and Y5 forms a hydrogen bond with the back-
bone structure of P-selectin. (C) Representative structure in neutral condi-
tions for a time period > ~10 ns, where Y5 has no contacts and Y7 forms
a contact with the backbone structure of P-selectin. (D) Representative
structure in acidic conditions for time periods < ~6 ns, where Y5 has
two hydrogen bonds with K8 and the backbone structure of P-selectin,
Y7 forms a hydrogen bond to H114, and Y10 is hydrogen bound to R85.
(E) Representative structure in acidic conditions for time periods >
~10 ns, where Y7 is still hydrogen bound to H114 and forms a hydrogen
bond with the P-selectin backbone structure, and R85 is now hydrogen
bound to sLeX.
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Figure 3.3: (A) 106 cells/ml of KG1a cells were perfused through MRE tubing 
functionalized with 2 mg/ml of recombinant human P-selectin/Fc at a wall shear stress 
of 7 dyn/cm2. (B and C) Protein-A-coated microspheres (106 beads/ml) functionalized 
with 14.47 mg/mg particles of recombinant human PSGL- 1/Fc (B), or with 0.017 mg/mg 
particles of sialyl Lewis-x-PAA-biotin (C) were perfused through MRE tubing 
functionalized with 10 mg/ml recombinant human P-selectin/Fc at a wall shear stress of 
1 dyn/cm2. Experiments were recorded for 1 min each at three randomly selected 
locations along the tube (unpaired t-test was performed; errors are mean 5 SE; *** p < 
0.0001; n = 3). Adapted from T. Cao et al. Biophys. J. 104, 292–299 (2013). 
 
 
 
 
environments. Interestingly, there was a remarkable differ-
ence in the dissociation dynamics depending on the proton-
ation state of H114. At the start of the simulation (Fig. 1),
the P-selectin/PSGL-1 complex conformations were nearly
identical where clear H114/Y7 and R85/Y10 contacts
were present, as suggested by Somers et al. (23). However,
after 6 ns in neutral conditions, R85 had already dissociated
from Y10 to form a hydrogen bond to sLeX (Fig. 2 B),
whereas in acidic conditions the R85/Y10 contact was
preserved (Fig. 2 D), most likely due to the increased inter-
action energy from the hydrogen-bonded H114/Y7 contact.
Moreover, Y5 was hydrogen-bonded to both K8 and the
P-selectin backbone, resulting in a total of four contacts in
acidic conditions, compared with two contacts in neutral
conditions. As PSGL-1 was pulled away from P-selectin
in neutral conditions, the Y5 and Y7 amino acids underwent
several sliding-rebinding events involving K8, K112, and
the P-selectin backbone, resulting in a force plateau from
8.5 to 10.5 ns. Subsequent to the numerous sliding-rebind-
ing events, Y5 was pulled too far to contact P-selectin
significantly (Fig. 2 C). In contrast, at ~9 ns in acidic condi-
tions, there was a rupture of all contacts (except for coordi-
nation bonding), signified by a dramatic decrease in the
pulling force. The R85 and Y7 contacts were then bonded
to sLeX and H114, respectively, while Y5 was kept within
the binding range of K8 and K112 (Fig. 2 E). On average,
the protonation of H114 increased the binding lifetime
by >1 ns, and therefore cells expressing PSGL-1 were
predicted to roll more slowly at slightly acidic pH than at
physiologically neutral pH on P-selectin surfaces.
P-selectin/PSGL-1 adhesion at acidic
pH—experimental rolling analysis
To further substantiate our SMD results, we investigated
P-selectin/PSGL-1 complex binding dynamics in acidic
environments in vitro by perfusing KG1a cell suspensions
through P-selectin-coated microtubes at varying pH levels
(6.2–7.4) with a flow rate of 0.111 ml/min, an equivalent
shear stress of 7 dyn/cm2 (Fig. 3 A). Cell rolling was con-
firmed to be specifically mediated by P-selectin/ PSGL-1
binding, because all interactions were abrogated when cells
were perfused in Ca2þ-free buffer containing 5 mM of
EDTA (data not shown). As the buffer pH level decreased
from 7.4 to 6.8, KG1a cells rolled more slowly, with the
average rolling velocity reaching a minimum of 4.25 5
0.21 mm/s at pH 6.8, suggesting longer P-selectin/PSGL-1
interaction lifetimes at slightly acidic pH levels. Conversely,
pH levels below 6.8 decreased the binding interaction life-
time of P-selectin to PSGL-1, which was manifested by an
increase in rolling velocity. Rolling-assay experiments
were also performed with PSGL-1 coated microspheres as
shown in Fig. 3 B. The microspheres exhibited rolling
characteristics similar to those of KG1a cells: the average
rolling velocity decreased at slightly acidic pH, with a
minimum at pH 6.6, and increased from the minimum at
pH levels below 6.6. This increase in rolling velocity may
be a consequence of the on-rate kinetics. Microspheres
that were functionalized with carbohydrate sLeX (effec-
tively eliminating the putative PSGL-1 backbone respon-
sible for hydrogen binding) did not exhibit enhanced
binding lifetime in slightly acidic environments (Fig. 3 C).
Circulating myeloid cells express PSGL-1 on their
surfaces, which serve as a counterreceptor for P-selectin
(34). As previously mentioned, P-selectin/ligand binding
facilitates the tethering and eventual rolling of myeloid cells
on the activated endothelial lining during physiological
events such as injury to the vessel wall and inflammation.
These phenomena are often coupled with a decrease in
pH level in the microenvironment where adhesion occurs
(35). The results of both the computational and experi-
mental studies presented here suggest that in slightly acidic
environments, the binding of the P-selectin/PSGL-1 com-
plex is enhanced due to the formation of a hydrogen
bond between the protonated H114 (P-selectin) and Y7
(PSGL-1) residues. Our findings suggest that during inflam-
mation, a drop in pH may have a contributory effect on re-
cruiting circulating myeloid cells by increasing the binding
FIGURE 3 (A) 106 cells/ml of KG1a cells were perfused through MRE tubing functionalized with 2 mg/ml of recombinant human P-selectin/Fc at a wall
shear stress of 7 dyn/cm2. (B and C) Protein-A-coated microspheres (106 beads/ml) functionalized with 14.47 mg/mg particles of recombinant human PSGL-
1/Fc (B), or with 0.017 mg/mg particles of sialyl Lewis-x-PAA-biotin (C) were perfused through MRE tubing functionalized with 10 mg/ml recombinant
human P-selectin/Fc at a wall shear stress of 1 dyn/c 2. Experiments were recorded for 1 min each at three rand mly selected locations along the tube
(unpaired t-test was performed; errors are mean5 SE; *** p < 0.0001; n ¼ 3).
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Figure 3.4: (A) Equilibrated L-selectin (blue) at physiologically neutral pH, where N138 
is hydrogen bound to the backbone structure of L-selectin. (B) Equilibrated L-selectin 
structure at physiologically acidic pH, where N138 is no longer close enough to form a 
hydrogen bond. All hydrogens except for those on the imidazoles of histidines are omitted 
for clarity, and the yellow sphere is the calcium ion. Adapted from T. Cao et al. Biophys. 
J. 104, 292–299 (2013). 
strength and lifetime between P-selectin to PSGL-1, which
slows cell rolling velocities at and around the target site.
L-selectin/PSGL-1 adhesion at acidic pH—MD
analysis
Given the good agreement between theory and experiment
for P-selectin, a similar computational analysis was per-
formed for L-selectin, as shown in Figs. 4 and 5. L-selectin
contains three histidine residues that potentially can be
protonated. The H4 and H130 residues had predicted pKa
values of 6.9 and 6.8 (Table 2), respectively, when not bound
to PSGL-1, and therefore likely change protonation states in
slightly acidic conditions. The main effect of protonating
these two residues in acidic conditions was the dissociation
of the hydrogen bond between the N138 residue (of the
EGF domain) and the lectin domain. This hydrogen bond
is important, because Phan et al. (36) found that a single
point mutation of N138 to glycine increased cell flux,
decreased cell rolling velocities, and increased the duration
of cell-tethering events. They suggested that these changes
were due to a greater L-selectin population in the extended
(high-affinity) conformation.
The predicted L-selectin/PSGL-1 complex showed an
increase of the H110 pKa value from 4.6 (unbound) to 6.5
(bound), and was also expected to be protonated in slightly
acidic conditions. The protonation of H110 dramatically
changed the PSGL-1 conformation, yielding a stacking
interaction between H110 and L13, and increased the likeli-
hood of hydrogen bonding between Y7 and the L-selectin
backbone (Fig. 5). SMD simulations demonstrated that
the protonation of H110 increased the L-selectin/PSGL-1
binding lifetime by >1.5 ns, as shown by the representative
SMD force versus time graphs in Fig. 5. A similar result was
FIGURE 4 (A) Equilibrated L-selectin (blue) at physiologically neutral
pH, where N138 is hydrogen bound to the backbone structure of L-selectin.
(B) Equilibrated L-selectin structure at physiologically acidic pH, where
N138 is no longer close enough to form a hydrogen bond. All hydrogens
except for those on the imidazoles of histidines are omitted for clarity,
and the yellow sphere is the calcium ion.
FIGURE 5 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from L-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time interval 1 represents a long force
plateau in the neutral case, where several sliding and rebinding events
occur. Time point 2 represents the complete rupture of all bonds, leading
to the dissociation of PSGL-1 from L-selectin in both conditions. (B and
C) Equilibrated PSGL-1 (magenta) and sLeX (orange) structures bound
to L-selectin (blue) at physiologically neutral pH. (D and E) Equilibrated
PSGL-1/L-selectin structure at physiologically acidic pH, where Y7 forms
contacts with the L-selectin backbone and L13 contacts H110 via a stacking
interaction.
TABLE 2 Predicted histidine pKa values for unbound L-
selectin (left) and L-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 6.9 7.1
H110 4.6 6.5
H130 6.8 6.9
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Figure 3.5: A Representative SMD force versus time graphs depicting the dissociation of 
PSGL-1 from L-selectin in physiologically neutral (red) and acidic (blue) conditions. 
Time interval 1 represents a long force plateau in the neutral case, where several sliding 
and rebinding events occur. Time point 2 represents the complete rupture of all bonds, 
leading to the dissociation of PSGL-1 from L-selectin in both conditions. (B and C) 
strength and lifetime between P-selectin to PSGL-1, which
slows cell rolling velocities at and around the target site.
L-selectin/PSGL-1 adhesion at acidic pH—MD
analysis
Given the good agreement between theory and experiment
for P-selectin, a similar computational analysis was per-
formed for L-selectin, as shown in Figs. 4 and 5. L-selectin
contains three histidine residues that potentially can be
protonated. The H4 and H130 residues had predicted pKa
values of 6.9 and 6.8 (Table 2), respectively, when not bound
to PSGL-1, and therefore likely change protonation states in
slightly acidic conditions. The main effect of protonating
these two residues in acidic conditions was the dissociation
of the hydrogen bond between the N138 residue (of the
EGF domain) and the lectin domain. This hydrogen bond
is important, because Phan et al. (36) found that a single
point mutation of N138 to glycine increased cell flux,
decreased cell rolling velocities, and increased the duration
of cell-tethering events. They suggested that these changes
were due to a greater L-selectin population in the extended
(high-affinity) conformation.
The predicted L-selectin/PSGL-1 complex showed an
increase of the H110 pKa value from 4.6 (unbound) to 6.5
(bound), and was also expected to be protonated in slightly
acidic conditions. The protonation of H110 dramatically
changed the PSGL-1 conformation, yielding a stacking
interaction between H110 and L13, and increased the likeli-
hood of hydrogen bonding between Y7 and the L-selectin
backbone (Fig. 5). SMD simulations demonstrated that
the protonation of H110 increased the L-selectin/PSGL-1
binding lifetime by >1.5 ns, as shown by the representative
SMD force versus time graphs in Fig. 5. A similar result was
FIGURE 4 (A) Equilibrated L-selectin (blue) at physiologically neutral
pH, where N138 is hydrogen bound to the backbone structure of L-selectin.
(B) Equilibrated L-selectin structure at physiologically acidic pH, where
N138 is no longer close enough to form a hydrogen bond. All hydrogens
except for those on the imidazoles of histidines are omitted for clarity,
and the yellow sphere is the calcium ion.
FIGURE 5 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from L-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time interval 1 represents a long force
plateau in the neutral case, where several sliding and rebinding events
occur. Time point 2 represents the complete rupture of all bonds, leading
to the dissocia ion of PSGL-1 from L-selec in i both conditions. (B and
C) Equilibrated PSGL-1 (magenta) and sLeX (orange) structures bound
to L-s lectin (blue) at physi logically neutral pH. (D and E) Equilibrat d
PSGL-1/L-selectin structure at physiologically acidic pH, where Y7 forms
contacts with the L-selectin backbone and L13 contacts H110 via a stacking
interaction.
TABLE 2 Predicted histidine pKa values for unbound L-
selectin (left) and L-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 6.9 7.1
H110 4.6 6.5
H130 6.8 6.9
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Equilibrated PSGL-1 (magenta) and sLeX (orange) structures bound to L-selectin (blue) 
at physiologically neutral pH. (D and E) Equilibrated PSGL-1/L-selectin structure at 
physiologically acidic pH, where Y7 forms contacts with the L-selectin backbone and L13 
contacts H110 via a stacking interaction. Adapted from T. Cao et al. Biophys. J. 104, 
292–299 (2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
strength and lifetime between P-selectin to PSGL-1, which
slows cell rolling velocities at and around the target site.
L-selectin/PSGL-1 adhesion at acidic pH—MD
analysis
Given the good agreement between theory and experiment
for P-selectin, a similar computational analysis was per-
formed for L-selectin, as shown in Figs. 4 and 5. L-selectin
contains three histidine residues that potentially can be
protonated. The H4 and H130 residues had predicted pKa
values of 6.9 and 6.8 (Table 2), respectively, when not bound
to PSGL-1, and therefore likely change protonation states in
slightly acidic conditions. The main effect of protonating
these two residues in acidic conditions was the dissociation
of the hydrogen bond between the N138 residue (of the
EGF domain) and the lectin domain. This hydrogen bond
is important, because Phan et al. (36) found that a single
point mutation of N138 to glycine increased cell flux,
decreased cell rolling velocities, and increased the duration
of cell-tethering events. They suggested that these changes
were due to a greater L-selectin population in the extended
(high-affinity) conformation.
The predicted L-selectin/PSGL-1 complex showed an
increase of the H110 pKa value from 4.6 (unbound) to 6.5
(bound), and was also expected to be protonated in slightly
acidic conditions. The protonation of H110 dramatically
changed the PSGL-1 conformation, yielding a stacking
interaction between H110 and L13, and increased the likeli-
hood of hydrogen bonding between Y7 and the L-selectin
backbone (Fig. 5). SMD simulations demonstrated that
the protonation of H110 increased the L-selectin/PSGL-1
binding lifetime by >1.5 ns, as shown by the representative
SMD force versus time graphs in Fig. 5. A similar result was
FIGURE 4 (A) Equilibrated L-selectin (blue) at physiologically neutral
pH, where N138 is hydrogen bound to the backbone structure of L-selectin.
(B) Equilibrated L-selectin structure at physiologically acidic pH, where
N138 is no longer close enough to form a hydrogen bond. All hydrogens
except for those on the imidazoles of histidines are omitted for clarity,
and the yellow sphere is the calcium ion.
FIGURE 5 (A) Representative SMD force versus time graphs depicting
the dissociation of PSGL-1 from L-selectin in physiologically neutral
(red) and acidic (blue) conditions. Time interval 1 represents a long force
plateau in the neutral case, where several sliding and rebinding events
occur. Time point 2 represents the complete rupture of all bonds, leading
to the dissociation of PSGL-1 from L-selectin in both conditions. (B and
C) Equilibrated PSGL-1 (magenta) and sLeX (orange) structures bound
to L-selectin (blue) at physiologically neutral pH. (D and E) Equilibrated
PSGL-1/L-selectin structure at physiologically acidic pH, where Y7 forms
contacts with the L-selectin backbone and L13 contacts H110 via a stacking
interaction.
TABLE 2 Predicted histidine pKa values for unbound L-
selectin (left) and L-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H4 6.9 7.1
H110 4.6 6.5
H130 6.8 6.9
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Figure 3.9 (A and B) Human neutrophils (106 cells/ml) (A) or protein-A-coated 
microspheres functionalized with 14.47 mg/mg particles of recombinant human L-
selectin/Fc (B) were perfused through MRE tubing functionalized with 10 mg/ml of 
discovered via the mutation of A108 of L-selectin (an amino
acid neighboring H110) to histidine, where the mutation
was proposed to increase the stacking interactions of L-se-
lectin and PSGL-1, resulting in an increased binding inter-
action (28). Therefore, an acidic pH environment should
produce considerable changes in the rolling profiles of cells
expressing L-selectin when perfused over PSGL-1-coated
surfaces via a change in selectin conformation and an
increased selectin/PSGL-1 binding interaction.
L-selectin/PSGL-1 adhesion at acidic pH—
experimental rolling analysis
Rolling-assay experiments with isolated human neutrophils
perfused through PSGL-1-coated microtubes showed that
the neutrophils maintained a statistically constant rolling
profile at pH levels ranging from 7.4 down to 6.6, but
steadily increased as the pH level became more acidic
than 6.6 (Fig. 6 A). Interestingly, pH had an effect on the
number of neutrophils that adhered and rolled on the
PSGL-1-coated surface, causing the cell flux to increase
in more acidic conditions over a range of shear stresses
(Fig. 6 C). This suggests that slightly acidic pH may
increase the binding frequency of L-selectin to PSGL-1,
as manifested by a higher rolling flux at lower pH.
Rolling-assay experiments using L-selectin-coated micro-
spheres perfused over PSGL-1-coated surfaces were also
conducted (Fig. 6 B). Interestingly, the microspheres rolled
more slowly at pH 7.2 than at 7.4, and remained at this
depressed velocity at pH levels as low as 6.4 before they
began to increase to higher velocities at pH levels below
6.4, indicating stronger L-selectin/PSGL-1 interactions at
slightly acidic pH. In contrast to a uniformly coated
microbead, the surface of neutrophils primarily express
L-selectin on the tips of microvilli (31,37). Neutrophils
use these L-selectin-decorated microvilli to attach to the tar-
geted surface expressing L-selectin receptors. Furthermore,
neutrophils can passively deform and modulate the number
of microvilli attached to the substrate in accordance with
external stimuli to allow maximum stability—a mechanism
that is unavailable to microspheres (38,39). These observa-
tions may explain why the effect of pH on L-selectin/
PSGL-1 interactions is more pronounced on rolling micro-
spheres than on neutrophils. However, the rolling flux for
the microspheres exhibited the same behavior as neutro-
phils: at lower pH conditions, a greater flux of rolling micro-
spheres was observed on PSGL-1-coated surfaces (data not
shown).
E-selectin/PSGL-1 adhesion at acidic pH—MD
analysis
To complete our study of selectins, we performed a pKa
analysis of E-selectin as shown in Fig. 7. In this case, only
two histidine residues were present, where the H25 pre-
dicted pKa was 6.8 (Table 3) and could change protonation
states in slightly acidic conditions. However, H25 is not
near the calcium ion and was not observed to increase amino
acid contacts between E-selectin and PSGL-1 (structure not
shown). Moreover, the N138 residue did not contact the lec-
tin domain in either neutral or acidic conditions. Hence, pH
is not expected to affect the binding strength or the binding
affinity of PSGL-1 to E-selectin, and no significant change
in rolling profiles is expected for cells expressing PSGL-1
when perfused over E-selectin-coated surfaces.
E-selectin/PSGL-1 adhesion at acidic pH—
experimental rolling analysis
Fig. 8 A displays the rolling velocity profile for KG1a cells
perfused through E-selectin-coated microtubes, where only
a steady rise in rolling velocities was observed as the pH
level became more acidic. However, the PSGL-1-coated
microspheres did not demonstrate any significant change
in rolling velocity at any pH level (Fig. 8 B). These data,
along with the computational predictions, indicate that the
pH range investigated in this study does not significantly
affect E-selectin/PSGL-1 binding dynamics.
FIGURE 6 (A and B) Human neutrophils (106 cells/ml) (A) or protein-A-coated microspheres functionalized with 14.47 mg/mg particles of recombinant
human L-selectin/Fc (B) were perfused through MRE tubing functionalized with 10 mg/ml of recombinant human PSGL-1/Fc at a wall shear stress of
2 dyn/cm2. (C) Human neutrophils (106 cells/ml) were perfused in buffer of indicated pH through MRE tubing functionalized with 10 mg/ml recombinant
human PSGL-1/Fc, and the number of rolling cells through the cross-sectional area of the tube was recorded for varying shear stresses (unpaired t-test; errors
are mean5 SE; ** p < 0.0012, *** p < 0.0001; n ¼ 3).
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recombinant human PSGL-1/Fc at a wall shear stress of 2 dyn/cm2. (C) Human 
neutrophils (106 cells/ml) were perfused in buffer of indicated pH through MRE tubing 
functionalized with 10 mg/ml recombinant human PSGL-1/Fc, and the number of rolling 
cells through the cross-sectional area of the tube was recorded for varying shear stresses 
(unpaired t-test; errors are mean 5 SE; ** p < 0.0012, *** p < 0.0001; n = 3 Adapted 
from T. Cao et al. Biophys. J. 104, 292–299 (2013).  
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Figure 3.10: (A) Equilibrated E-selectin (green) at physiologically neutral pH. (B) 
Equilibrated E-selectin structure at physiologically acidic pH. All hydrogens except for 
those on the imidazoles of histidines are omitted for clarity, and the yellow sphere is the 
calcium ion. Adapted from T. Cao et al. Biophys. J. 104, 292–299 (2013).CONCLUSIONS
Acidic extracellular pH does indeed alter the adhesion
dynamics of certain selectins to PSGL-1, which causes
differential rolling and adhesion characteristics of cells
dependent on selectin-mediated rolling. P-selectin/PSGL-1
binding was enhanced at slightly acidic pH due to the
formation of a new hydrogen bond between H114 (P-selec-
tin) and Y7 (PSGL-1). As a result, the P-selectin/PSGL-1
binding lifetime increased, and, correspondingly, cell roll-
ing velocities on P-selectin-coated surfaces were ex-
perimentally shown to decrease. When cells expressing
L-selectin were perfused through PSGL-1-coated micro-
tubes, cell flux increased at slightly acidic pH, whereas
rolling velocities remained unchanged. The cell flux is
primarily due to the altered structure of L-selectin at acidic
pH, where the hydrogen bond between residue N138 (EGF
domain) and the lectin-binding domain is dissociated as
a result of protonating the H4 and H130 residues. The disso-
ciation of this hydrogen bond allows L-selectin to assume
a more flexible conformation (high affinity) that results in
improved frequency of binding to PSGL-1. On the other
hand, residue H110 is also predicted to be protonated
when bound to L-selectin in acidic conditions that increase
contacts and strengthen the binding interaction. We only
observed this effect (i.e., slower rolling velocity) when we
eliminated cellular effects by using L-selectin-coated micro-
spheres. A previous study by Serrano et al. (19) also showed
that neutrophil recruitment is enhanced in acidic conditions
due to the upregulation of CD18 by the neutrophils. In this
study, we showed that before firm adhesion facilitated by the
CD18/ICAM-1 interaction occurs, acidic pH also enhances
neutrophil recruitment in the initial step of the adhesion
cascade through the mediation of L-selectin/PSGL-1 bind-
ing dynamics. In contrast to P- and L-selectin, E-selectin/
PSGL-1 binding was not significantly affected by acidic
pH. In conclusion, both theoretical predictions and experi-
mental observations indicate that the extracellular pH level
modulates selectin adhesion under flow. Thus, the extracel-
lular pH level may serve as an external signaling stimulus
for leukocytes trafficking during the inflammatory response.
These results further suggest an additional axis that can be
used to control applications such as the selectin-based isola-
tion of CTCs and hematopoietic stem cells (33,40).
This work was funded by the National Institutes of Health (grants
HL018128 and HL097971).
The authors thank Jeff Mattison for blood collection work.
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FIGURE 7 (A) Equilibrated E-selectin (green) at physiologically neutral
pH. (B) Equilibrated E-s lectin structure at physiologi ll acidic . All
hydrogens except for those on the imidazoles of histidines are omitted
for clarity, and the yellow sphere is the calcium ion.
TABLE 3 Predicted histidine pKa values for unbound
E-selectin (left) and E-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H25 6.8 6.6
H130 7.8 7.4
FIGURE 8 (A and B) KG1a cells (106 cells/ml) (A) or protein-A-coated
microspheres functionalized with 14.47 mg/mg particles of recombinant
human E-Sel/Fc (B) were perfused through MRE tubing functionalized
with 2 mg/ml of recombinant human E-selectin/Fc at a wall shear stress
of 7 dyn/cm2 (unpaired t-test; errors are mean 5 SE; *** p < 0.0001;
n ¼ 3).
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Figure 3.11: (A and B) KG1a cells (106 cells/ml) (A) or protein-A-coated microspheres 
functionalized with 14.47 mg/mg particles of recombinant human E-Sel/Fc (B) were 
perfused through MRE tubing functionalized with 2 mg/ml of recombinant human E-
selectin/Fc at a wall shear stress of 7 dyn/cm2 (unpaired t-test; errors are mean 5 SE; 
*** p < 0.0001; n = 3). Adapted from T. Cao et al. Biophys. J. 104, 292–299 (2013). 
 
 
 
 
 
 
 
CONCLUSIONS
Acidic extracellular pH does indeed alter the adhesion
dynamics of certain selectins to PSGL-1, which causes
differential rolling and adhesion characteristics of cells
dependent on selectin-mediated rolling. P-selectin/PSGL-1
binding was enhanced at slightly acidic pH due to the
formation of a new hydrogen bond between H114 (P-selec-
tin) and Y7 (PSGL-1). As a result, the P-selectin/PSGL-1
binding lifetime increased, and, correspondingly, cell roll-
ing velocities on P-selectin-coated surfaces were ex-
perimentally shown to decrease. When cells expressing
L-selectin were perfused through PSGL-1-coated micro-
tubes, cell flux increased at slightly acidic pH, whereas
rolling velocities remained unchanged. The cell flux is
primarily due to the altered structure of L-selectin at acidic
pH, where the hydrogen bond between residue N138 (EGF
domain) and the lectin-binding domain is dissociated as
a result of protonating the H4 and H130 residues. The disso-
ciation of this hydrogen bond allows L-selectin to assume
a more flexible conformation (high affinity) that results in
improved frequency of binding to PSGL-1. On the other
hand, residue H110 is also predicted to be protonated
when bound to L-selectin in acidic conditions that increase
contacts and strengthen the binding interaction. We only
observed this effect (i.e., slower rolling velocity) when we
eliminated cellular effects by using L-selectin-coated micro-
spheres. A previous study by Serrano et al. (19) also showed
that neutrophil recruitment is enhanced in acidic conditions
due to the upregulation of CD18 by the neutrophils. In this
study, we showed that before firm adhesion facilitated by the
CD18/ICAM-1 interaction occurs, acidic pH also enhances
neutrophil recruitment in the initial step of the adhesion
cascade through the mediation of L-selectin/PSGL-1 bind-
ing dynamics. In contrast to P- and L-selectin, E-selectin/
PSGL-1 binding was not significantly affected by acidic
pH. In conclusion, both theoretical predictions and experi-
mental observations indicate that the extracellular pH level
modulates selectin adhesion under flow. Thus, the extracel-
lular pH level may serve as an external signaling stimulus
for leukocytes trafficking during the inflammatory response.
These results further suggest an additional axis that can be
used to control applications such as the selectin-based isola-
tion of CTCs and hematopoietic stem cells (33,40).
This work was funded by the National Institutes of Health (grants
HL018128 and HL097971).
The authors thank Jeff Mattison for blood collection work.
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FIGURE 7 (A) Equilibrated E-selectin (green) at physiologically neutral
pH. (B) Equilibrated E-selectin structure at physiologically acidic pH. All
hydrogens except for those on the imidazoles of histidines are omitted
for clarity, and the yellow sphere is the calcium ion.
TABLE 3 Predicted histidine pKa values for unbound
E-selectin (left) and E-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H25 6.8 6.6
H130 7.8 7.4
FIGURE 8 (A and B) KG1a cells (106 cells/ml) (A) or protein-A-coated
microspheres functionalized with 14.47 mg/mg particles of recombinant
human E-Sel/Fc (B) were perfused through MRE tubing functionalized
with 2 mg/ml of recombinant human E-selectin/Fc at a wall shear stress
of 7 yn/cm2 (unpaired t-test; errors are mean 5 SE; *** p < 0.0001;
n ¼ 3).
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CONCLUSIONS
Acidic extracellular pH does indeed alter the adhesion
dynamics of certain selectins to PSGL-1, which causes
differential rolling and adhesion characteristics of cells
dependent on selectin-mediated rolling. P-selectin/PSGL-1
binding was enhanced at slightly acidic pH due to the
formation of a new hydrogen bond between H114 (P-selec-
tin) and Y7 (PSGL-1). As a result, the P-selectin/PSGL-1
binding lifetime increased, and, correspondingly, cell roll-
ing velocities on P-selectin-coated surfaces were ex-
perimentally shown to decrease. When cells expressing
L-selectin were perfused through PSGL-1-coated micro-
tubes, cell flux increased at slightly acidic pH, whereas
rolling velocities remained unchanged. The cell flux is
primarily due to the altered structure of L-selectin at acidic
pH, where the hydrogen bond between residue N138 (EGF
domain) and the lectin-binding domain is dissociated as
a result of protonating the H4 and H130 residues. The disso-
ciation of this hydrogen bond allows L-selectin to assume
a more flexible conformation (high affinity) that results in
improved frequency of binding to PSGL-1. On the other
hand, residue H110 is also predicted to be protonated
when bound to L-selectin in acidic conditions that increase
contacts and strengthen the binding interaction. We only
observed this effect (i.e., slower rolling velocity) when we
eliminated cellular effects by using L-selectin-coated micro-
spheres. A previous study by Serrano et al. (19) also showed
that neutrophil recruitment is enhanced in acidic conditions
due to the upregulation of CD18 by the neutrophils. In this
study, we showed that before firm adhesion facilitated by the
CD18/ICAM-1 interaction occurs, acidic pH also enhances
neutrophil recruitment in the initial step of the adhesion
cascade through the mediation of L-selectin/PSGL-1 bind-
ing dynamics. In contrast to P- and L-selectin, E-selectin/
PSGL-1 binding was not significantly affected by acidic
pH. In conclusion, both theoretical predictions and experi-
mental observations indicate that the extracellular pH level
modulates selectin adhesion under flow. Thus, the extracel-
lular pH level may serve as an external signaling stimulus
for leukocytes trafficking during the inflammatory response.
These results further suggest an additional axis that can be
used to control applications such as the selectin-based isola-
tion of CTCs and hematopoietic stem cells (33,40).
This work was funded by the National Institutes of Health (grants
HL018128 and HL097971).
The authors thank Jeff Mattison for blood collection work.
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FIGURE 7 (A) Equilibrated E-selectin (green) at physiologically neutral
pH. (B) Equilibrated E-selectin structure at physiologically acidic pH. All
hydrogens except for those on the imidazoles of histidines are omitted
for clarity, and the yellow sphere is the calcium ion.
TABLE 3 Predicted histidine pKa values for unbound
E-selectin (left) and E-selectin bound to PSGL-1 (right)
Residue pKa pKa*
H25 6.8 6.6
H130 7.8 7.4
FIGURE 8 (A and B) KG1a cells (106 cells/ml) (A) or protein-A-coated
microspheres functionalized with 14.47 mg/mg particles of recombinant
human E-Sel/Fc (B) were perfused through MRE tubing functionalized
with 2 mg/ml of recombinant human E-selectin/Fc at a wall shear stress
of 7 dyn/cm2 (unpaired t-test; errors are mean 5 SE; *** p < 0.0001;
n ¼ 3).
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CHAPTER 4 
Stem Cell Enrichment with Selectin Receptors: Mimicking the pH 
Environment of Trauma 
This chapter was published in the Sensors (177). 
4.1 ABSTRACT 
The isolation of hematopoietic stem and progenitor cells (HSPCs) is critical for 
transplantation therapy and HSPC research, however current isolation techniques can be 
prohibitively expensive, time-consuming, and produce variable results. Selectin-coated 
microtubes have shown promise in rapidly isolating HSPCs from human bone marrow, 
but further purification of HSPCs remains a challenge. Herein, a biomimetic device for 
HSPC isolation is presented to mimic the acidic vascular microenvironment during 
trauma, which can enhance the binding frequency between L-selectin and its counter-
receptor PSGL-1 and HSPCs. Under acidic pH conditions, L-selectin coated microtubes 
enhanced CD34+ HSPC adhesion, as evidenced by decreased cell rolling velocity and 
increased rolling flux. Dynamic light scattering was utilized as a novel sensor to confirm 
an L-selectin conformational change under acidic conditions, as previously predicted by 
molecular dynamics. These results suggest that mimicking the acidic conditions of trauma 
can induce a conformational extension of L-selectin, which can be utilized for flow-
based, clinical isolation of HSPCs.  
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4.2 INTRODUCTION  
Human hematopoietic stem and progenitor cells (HSPCs) originating from the bone 
marrow (BM) play a critical role in treating many hematological malignancies due to their 
unique multipotent, stem cell quality (178, 179). In cancer patients with depleted immune 
cells, HSPCs transplantation is used to repopulate blood cell lineages (180, 181). On the 
other hand, increasing evidence has shown that mutagenesis which occurs during the 
development of HSPCs converts these cells to leukemic stem cells (182, 183). Therefore, 
a reliable and simple means for the acquisition and enrichment of HSPCs for both 
transplantation therapy and to better understand leukemia is needed. HSPCs routinely 
leave the BM to enter the circulatory system and distant tissues to establish and maintain 
hematopoiesis (184–187). During embryogenesis, HSPCs migrate to the fetal liver and 
differentiate (188–190). In adults, HSPCs participate in the innate immune response 
against foreign antigens (191–193). HSPCs express a repertoire of surface ligands that 
include unique markers as well as markers shared with leukocytes and circulating tumor 
cells  (64, 66) that can bind the family of adhesion molecules called selectins (E-, L- and 
P-), which facilitates their migration from (and to) the BM and distant tissues (169, 194–
197). In a recent study, we observed that acidic extracellular pH enhances L-
selectin:PSGL-1 interactions under flow (136). Extracellular pH becomes acidic during 
the early stages of wound healing and inflammation (198, 199) which is also a period of 
elevated recruitment of HSPCs to target sites (200, 201). It follows that HSPCs may 
experience altered adhesion due to L-selectin:ligand binding in acidic environments. In 
this study, we determined that L-selectin ligands expressed on the surface of HSPCs bind 
with enhanced affinity to L-selectin under acidic extracellular pH. Furthermore, the 
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enhanced L-selectin:ligand binding affinity is due to L-selectin undergoing 
conformational change in acidic pH as quantified by dynamic light scattering 
measurements of selectin-PEG-decocorated liposomes. Finally, by mimicking this 
physiological phenomenon, we demonstrate its potential use to capture and enrich HSPCs 
by perfusing a suspension of BM cells through L-selectin coated microtubes under acidic 
pH.  
4.3 MATERIALS AND METHODS 
Reagents and Antibodies  
Phosphate-buffered saline (PBS) and Hank’s balanced salt solution (HBSS) were 
purchased from Invitrogen (Grand Island, NY, USA). Recombinant human P-, L-, and E-
selectin/IgG chimera were purchased from R&D Systems (Minneapolis, MN, USA). 
Phycoerythrin (PE)-conjugated mouse anti-human CD34 (clone 581) and PE-conjugated 
mouse IgG1 κ-isotype control were purchased from Biolegend (San Diego, CA, USA). 
APC-conjugated mouse anti-human L-selectin (clone DREG-56) was purchased from BD 
Biosciences (San Jose, CA, USA).  
Isolation of Bone Marrow  
Cells Bone narrow mononuclear cells (MNCs) were extracted from consenting adult 
donors following a protocol approved by the Research Subjects Review Board of the 
University of Rochester, as described previously (169). Briefly, bone marrow samples 
were diluted 3-fold (vol/vol) in Ca2+ and Mg2+-free PBS, with 35 mL of the diluted 
sample carefully layered over 15 mL Ficoll cell separation solution (GE Healthcare, 
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Piscataway, NJ, USA) in 50 mL Falcon tubes. Samples were then centrifuged at 800 g 
for 20 min at RT to separate bone marrow MNCs from excess cells and tissue debris. The 
buffy coat of MNCs was extracted and place into a separate tube and washed twice in 
PBS. Bone marrow MNCs were quantified and placed in flow buffer (PBS supplemented 
with Ca2+) for flow-based assays.  
Isolation of CD34+ Population using Microbeads  
To characterize the rolling characteristics of CD34+ HSPCs in acidic pH, CD34+ bone 
marrow HSPCs were isolated using EasySep Human CD34 Positive Selection Kit by 
StemCell Technology (Vanvouver, BC, Canada) per manufacturer’s instructions. Briefly, 
a solution of mononuclear cells was incubated with tetrameric antibody complexes 
against CD34 for 15 min, followed by incubation with dextran-coated magnetic 
nanoparticles (MNP) for 10 min. The cell-containing tube was then placed in an 
EasySep® magnet for positive selectin, allowing the MNP-conjugated CD34+ cells to 
remain in the tube while the supernatant was poured off. The cell population was washed, 
and the magnetic separation was repeated until the desired purity was achieved.  
Microtube Functionalization  
Micro-renathane (MRE) tubes (300 µm inner diameter, 50 cm long; Braintree Scientific, 
Braintree, MA, USA) were sterilized with 80% ethanol for 10 min. The tubes were then 
washed (3×) with PBS buffer (Ca2+-free). The inner surface was functionalized with 
recombinant human L-selectin/Fc at specified concentration for 2 h. The microtubes were 
then incubated in PBS supplemented with dry milk (5% w/v; Sigma-Aldrich, St. Louis, 
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MO, USA) for 1 h to prevent nonspecific adhesion. All steps were performed at room 
temperature (RT). In several experiments microtubes were labeled with APC conjugated 
mouse anti human L-selectin for 30 min. Microtubes were washed three times with buffer 
and images were acquired on an inverted research microscope (Olympus America, 
Melville, NY, USA).  
Flow-Based Cell Adhesion Assay  
Cells suspended in PBS buffer (supplemented with 2 mM Ca2+) at a specified pH (6.6 or 
7.4) were perfused through functionalized microtubes using a syringe pump at a wall 
shear stress of 2.0 dynes (dyn)/cm2 . Videos of rolling cells were captured and analyzed 
using ImageJ (US National Institutes of Health, Bethesda, MD, USA). Cell rolling 
velocity was determined by measuring the displacement of a rolling cell over time, while 
rolling flux was determined by quantifying the number of rolling cells entering the image 
frame over the course of 1 min. 2.6. CD34+ HSPC Flow-Based Isolation A cell 
suspension of bone marrow MNCs (5 × 106 cell/mL) in PBS buffer (supplemented with 
2 mM Ca2+) at specified pH was perfused through L-selectin functionalized microtubes 
at a wall shear stress of 1.0 dyn/cm2. To collect captured cells, the microtube was 
incubated with fresh PBS buffer (Ca2+ free and supplemented with 2 mM of EDTA) for 
15 min, and then the cell gently collected into a 1.5 mL Eppendorf tube. Captured cells 
were also detached from the surface via air embolism. An air bubble is introduced into 
the microtube using an empty syringe. The bubble is then slowly pushed through the 
entire length of the microtube to dislodge any remaining captured cells into the collecting 
tube at the opposing end.  
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Preparation of Selectin-Conjugated Liposomes  
Multilamellar liposomes were prepared using a thin lipid film hydration method as 
previously described (202, 203). Briefly, lipids were hydrated in 125 mM ammonium 
sulfate (Sigma-Aldrich) to form multilamellar liposomes, followed by 10 freeze-thaw 
cycles and then extrusion as previously described (204, 205) to prepare unilamellar 
liposomes. Recombinant human E-, L-, and P-selectin/Fc chimera (rhE/Fc) (R&D 
Systems, Minneapolis, MN, USA) was conjugated to 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-maleimide 2000 (DSPE-PEG2000 maleimide) (Avanti Polar 
Lipids, Alabaster, AL, USA) via thiolation, and PEG or selectin-PEG conjuguates were 
covalently attached to diluted unilamellar liposomes as described previously (206). All 
liposomes were stored at 4 °C for no more than one week until usage.  
Dynamic Light Scattering  
To detect changes in selectin protein conformation, freshly prepared selectin-conjugated 
liposomes (<24 h) were diluted (1,000×) in buffer at specified pH. To remove aggregates, 
samples were filtered through a 0.45 μm filter (MicroLiter Analytical Supplies, Inc., 
Suwanee, GA, USA). Samples were analyzed for changes in particle size and 
polydispersity index (PDI) using a Malvern Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK).  
Flow Cytometry  
Isolated cells were stained with mouse anti-human CD34 (clone 581), or mouse IgG1 κ-
isotype purchased from Biolegend (San Diego, CA, USA). Cells were washed twice with 
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PBS (supplemented with 1% BSA) and then incubated with antibody at 4 °C for 30 min. 
Cells were washed twice with buffer and analyzed using a Guava EasyCyte flow 
cytometer (Millipore, Billerica, MA, USA). CD34+ post-isolation cell populations were 
quantified and plotted using FlowJo software (Treestar Inc., San Carlos, CA, USA).  
Statistical Analysis  
Cell rolling velocity and flux were plotted and statistically analyzed using Prism 
(GraphPad Software, San Diego, CA, USA). Two-tailed unpaired t-test was used to 
determine statistical significance.  
4.4 RESULTS AND DISCUSSION 
CD34+ Human BM Cell Interaction with L-Selectin is Enhanced under Acidic 
Extracellular pH  
To characterize the influence of acidic extracellular pH on the interaction of human 
HSPCs and L-selectin, CD34+ cells were perfused through microtubes coated with L-
selectin (Figure 4.1A) at 2 dyn/cm2. This level of shear stress was chosen because it is 
within the physiological shear stress range that mononuclear cells experience in the 
human circulatory system. CD34+ cells exhibited a significantly lower rolling velocity 
on L-selectin under acidic conditions (Figure 4.1D), when compared to L-selectin 
mediated CD34+ cell rolling at a pH of 7.4. At pH 6.6, CD34+ cells had an average rolling 
velocity of 22.14 ± 1.87 μm/s, compared to an average rolling velocity of 31.24 ± 3.23 
μm/s at pH 7.4. This indicates that under acidic conditions, CD34+ HSPCs experience 
enhanced binding to L-selectin. To show that the observed interaction between the 
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perfused cells and the coated microtube is L-selectin:ligand specific, cells were perfused 
through microtubes coated with milk alone. Cell adhesion was not observed in this case 
(Figure 1B). In contrast, microtubes coated with L-selectin showed extensive cell rolling 
and adhesion (Figure 4.1C). In addition, Ca2+-dependent cell rolling (207, 208) was 
abrogated by perfusion with HBSS (Ca2+ free buffer supplemented with 2mM EDTA) 
(data not shown) thus confirming that cell interaction was mediated specifically by L-
selectin:ligand adhesion. The average rolling velocity of CD34+ cells was significantly 
lower compared to MNCs from bone marrow (Figure 4.1E). This observation supports 
previous work, which suggested that CD34+ cells have stronger binding affinity to L-
selectin than CD34- cells (209). In contrast, no significant differences in CD34- cells 
were observed under physiological and acidic pH conditions (Figure 4.1E). An increase 
in cell rolling flux of MNCs in acidic pH was also found, in comparison to the cell flux 
measured at physiological pH (Figure 4.2). These results suggest that acidic pH can be 
utilized to enhance the number of cell interactions with the L-selectin coating, thus 
improving the number of cells captured.  
Previous work showed that L-selectin can adopt an “extended” (high affinity) 
conformation with a point mutation of an amino acid in the EGF domain of L-selectin 
(172). This extended conformation results in decreased cell rolling velocity, and an 
increase in cell flux on the L-selectin ligand PSGL-1. Furthermore, it was previously 
established that pH can encourage L-selectin to adopt this extended, high affinity 
conformation due to the abolition of hydrogen bonding between the EGF and lectin 
domains of L-selectin which normally confines the protein in the “low affinity” 
conformation (136). Therefore, we sought to determine whether acidic pH can induce a 
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measurable, extended conformation of L-selectin. Dynamic light scattering (DLS) was 
utilized to determine changes in the protein size of selectins (E, P and L) presented on 
nanoscale liposomes in buffer at specified pH. While liposomes in the absence of selectin 
protein (Table 4.1) or conjugated with E- or P-selectin exhibited minimal, non-significant 
changes in hydrodynamic radius (Figure 4.3), L-selectin significantly increased its 
average length by 1.3 nm (Figure 4.3, Table 4.1) as evidenced by an increase in 
hydrodynamic radius.  
Together, these results indicate that, in comparison to physiological pH, L-selectin can 
extend its conformation under acidic pH, which is consistent with an observed 
enhancement in CD34+ cell adhesion. An extended conformation of L-selectin can allow 
the protein to bind to its ligands more strongly and at higher frequency, as evidenced by 
a lower CD34+ cell rolling velocity and increased flux (Figure 4.4).  
Selectin-coated microdevices have been shown to effectively capture viable stem cells 
(210, 211) and circulating tumor cells from whole blood with high yield (212). To mimic 
the physiological phenomenon of L-selectin:ligand interaction under acidic conditions for 
the isolation and enrichment of CD34+ bone marrow cells, low-density bone marrow 
cells isolated from healthy adult donors using Ficoll were perfused at a concentration 5 × 
106 cells/ml through L-selectin coated microtubes (50 μg/mL) at 1.0 dyn/cm2 in PBS 
buffer supplemented with 2 mM Ca2+. Adherent cells were dislodged from the surface 
using both buffer supplemented with 2 mM EDTA and air embolism. Isolated cells were 
stained using an anti-CD34 monoclonal antibody. L-selectin coated microtubes were 
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found to capture and enrich CD34+ HSPCs from the bone marrow at >19% purity (Figure 
4.5).  
4.5 CONCLUSIONS  
During tissue inflammation, extracellular pH can become increasingly acidic. 
Furthermore, it is also known that HSPCs are recruited to sites of inflammation via 
selectin-mediated cell rolling. In this study, we showed that acidic extracellular pH 
enhances CD34+ HSPCs adhesion to L-selectin, consistent with a measurable extended 
conformational change of L-selectin to a “high affinity” orientation in acidic pH. This 
conformational change is taken to increase the frequency of L-selectin:ligand binding. 
These biophysical insights were applied to the isolation and enrichment of CD34+ HSPCs 
from bone marrow using an L-selectin coated microtube. The described biomimetic 
technique allows for both rapid and simple isolation of viable CD34+ HSPCs from patient 
bone marrow.  
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Figure 4.1: Enhanced adhesion of CD34+ cells to L-selectin at acidic pH. (A) Relative 
fluorescence intensity of L-selectin coated and blank microtubes labeled with APC-anti 
human L-selectin. (B–C) Images of perfused cells interacting with blank or functionalized 
microtubes, respectively. Scale bars are 100 μm. (D) Rolling velocity of CD34+ cells 
under normal (7.4) and acidic (6.6) pH. CD34+ cells at a concentration of 1 × 106 
cells/mL were perfused through L-selectin coated (20 μg/mL) microtubes at a shear stress 
of 2.0 dyn/cm2 in buffer at specified pH. (E) Comparison of rolling velocities of CD34+ 
cells and MNCs (unpaired t-test, error bars indicate standard error of the mean; * p < 
0.05, **** p < 0.0001; n = 3). Adapted from T. Cao et al. Sensors (Switzerland) (2013). 
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Table 4.1: Mean particle radius and polydispersity index (PDI) measurements of selectin-
coated liposome samples under neutral and acidic conditions. Data reported as mean ± 
standard deviation. Results recorded in triplicate. Adapted from T. Cao et al. Sensors 
(Switzerland) (2013). 
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Figure 4.2: MNCs isolated from bone marrow display higher binding affinity to L-selectin 
in acidic pH. A suspension of MNCs (1 × 106 cells/mL) was perfused through L-selectin 
coated (20 μg/mL) microtubes at a shear stress of 2.0 dyn/cm2 in buffer at specified pH. 
Cell rolling flux was measured by counting the number of rolling cells crossing into the 
image frame over 1 min (unpaired t-test, error bars indicate standard error of the mean; 
* p < 0.05; n = 3). Adapted from T. Cao et al. Sensors (Switzerland) (2013). 
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Figure 4.3: Extension of E-, L-, and P-selectin protein size (in nanometers) upon 
exposure to acidic (pH 6.6) conditions. Changes in E-, L-, and P-selectin protein size 
were determined using dynamic light scattering by subtracting the mean particle radius 
of selectin-coated liposomes under neutral conditions from the mean particle radius of 
selectin-coated liposomes under acidic conditions. * p < 0.05. NS = not significant. 
Adapted from T. Cao et al. Sensors (Switzerland) (2013). 
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Figure 4.4: Schematic of increased HSPC adhesion to L-selectin in high affinity, 
extended conformation under acidic pH (B) compared to the lower affinity, bent 
conformation (A). Adapted from T. Cao et al. Sensors (Switzerland) (2013). 
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Figure 4.5: L-selectin mediated isolation of CD34+ cells from patient bone marrow 
samples under acidic pH. Captured cells were labeled using a mouse anti-human CD34 
monoclonal antibody. Flow cytometry plots are a representation of experiments done in 
triplicate. SSC = side scatter. Adapted from T. Cao et al. Sensors (Switzerland) (2013). 
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CHAPTER 5 
Comparison of human and mouse E- selectin binding to Sialyl-Lewis
x 
 
This chapter was published in the Sensors (213). 
5.1 ABSTRACT  
Background: During inflammation, leukocytes are captured by the selectin family of 
adhesion receptors lining blood vessels to facilitate exit from the bloodstream. E-selectin 
is upregulated on stimulated endothelial cells and binds to several ligands on the surface 
of leukocytes. Selectin:ligand interactions are mediated in part by the interaction between 
the lectin domain and Sialyl-Lewis x (sLex), a tetrasaccharide common to selectin 
ligands. There is a high degree of homology between selectins of various species: about 
72 and 60 % in the lectin and EGF domains, respectively. In this study, molecular 
dynamics, docking, and steered molecular dynamics simulations were used to compare 
the binding and dissociation mechanisms of sLex with mouse and human E-selectin. First, 
a mouse E-selectin homology model was generated using the human E-selectin crystal 
structure as a template.  
Results: Mouse E-selectin was found to have a greater interdomain angle, which has been 
previously shown to correlate with stronger binding among selectins. sLex was docked 
onto human and mouse E-selectin, and the mouse complex was found to have a higher 
free energy of binding and a lower dissociation constant, suggesting stronger binding. 
The mouse complex had higher flexibility in a few key residues. Finally, steered 
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molecular dynamics was used to dissociate the complexes at force loading rates of 2000–
5000 pm/ps2. The mouse complex took longer to dissociate at every force loading rate 
and the difference was statistically significant at 3000 pm/ps2. When sLex-coated 
microspheres were perfused through microtubes coated with human or mouse E-selectin, 
the particles rolled more slowly on mouse E-selectin.  
Conclusions: Both molecular dynamics simulations and microsphere adhesion 
experiments show that mouse E-selectin protein binds more strongly to sialyl Lewis x 
ligand than human E-selectin. This difference was explained by a greater interdomain 
angle for mouse E-selectin, and greater flexibility in key residues. Future work could 
introduce similar amino acid substitutions into the human E-selectin sequence to further 
modulate adhesion behavior.  
Keywords: E-selectin, Receptor, Cell adhesion, Molecular dynamics, Docking, Steered 
molecular dynamics  
5.2 INTRODUCTION  
Selectins are a family of transmembrane adhesion molecules that mediate the 
inflammatory response and the cancer metastasis cascade. There are three members of 
the selectin family: P(latelet)-selectin, E(ndothelial)-selectin, and L(eukocyte)-selectin. 
All three contain an N-terminal lectin domain, epidermal-growth-factor-like (EGF) 
domain, a varying number of consensus repeat units, a transmembrane portion, and a 
cytoplasmic tail (170, 214, 215). During inflammation, fast binding and dissociation of 
bonds between cells and endothelium contributes to rolling. Selectin:ligand interactions 
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are mediated partially by the interaction between the lectin domain and Sialyl Lewis x 
(sLex), a tetra saccharide on cell surface proteins common to selectin ligands. E-selectin 
binds particularly well to PSGL-1, CD44, and ESL-1 (170, 216).  
There is a high degree of amino acid identity between selectins of various species: about 
72 and 60 % in the lec- tin and EGF domains, respectively (215). Mouse E-selectin differs 
from human E-selectin by 29 substitutions in the lectin and EGF domains (Figure 5.1). 
The amino acid differences between human and mouse E-selectin are fairly evenly 
distributed within and between the domains (Figure 5.1).  
Molecule conformational changes are essential to physio- logical processes (217). 
Selectin interdomain hinge flexibility greatly affects the on-rate of selectin:ligand 
binding. All the selectins have shown “open” and “closed” states that correspond to 
whether or not they are in complex; for instance, there is a 52° increase in the interdomain 
angle from unliganded P-selectin to P-selectin in complex (159). Hydro- dynamic forces 
in the bloodstream favor the open conformation as it can strengthen selectin:ligand bonds 
(172). A flexible hinge encourages the oscillation between the two states, which 
facilitates greater range of motion for the lectin domain and thus provides more 
opportunity for binding (218, 219). Lou et al. used molecular dynamics (MD) and site 
mutagenesis at the interdomain hinge of L-selectin to learn that increasing hinge 
flexibility via mutation caused an in- crease in binding on- and off-rates of selectin:ligand 
interactions (166). Of particular interest are the binding site and interdomain angle, since 
prior dissociation studies of P- selectin:sLex suggest these to be important modulators of 
dissociation time and final conformation (220).  
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MD simulations are a useful tool to study the movement of a protein chain over time, 
given specified starting parameters (221). The goal of this study was to determine how 
the structural differences between human and mouse E-selectin affect their corresponding 
binding and thus cell rolling behavior. MD, docking, and steered molecular dynamics 
(SMD) were used in conjugation with microtube rolling experiments to address this link 
between molecular properties and cellular scale adhesion phenomena under flow.  
5.3 MATERIALS AND METHODS  
MD to prepare receptor (E-selectin or mutants) for docking the lectin and EGF crystal 
structure of human E- selectin (1ESL) was obtained from the Protein Data Bank to 
provide starting atomic coordinates. The lectin and EGF domains are the effective binding 
unit of E-selectin.  
The E-selectin:sLex complex crystal structure (1G1T) was not used as a starting structure 
as the bound com- plex does not allow for full flexibility of E-selectin when amino acid 
substitutions are made. MD, docking, and SMD simulations were performed using the 
YASARA (YASARA Biosciences GmbH, Vienna, Austria) package of MD programs 
with the YAMBER3 self-parameterizing force field. For all simulations, the temperature 
and pressure were held constant at 298 K and 1 atm, respectively. Other parameters used 
include periodic boundary conditions, the particle mesh Ewald method for electro- static 
interactions, and the recommended 7.86 Å force cutoff for long-range interactions (136). 
A predicted model of mouse E-selectin was created using human E- selectin as a template 
and substituting 29 residues.  
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For equilibrium simulations, human and mouse E- selectin were each solvated in a water 
box and neutralized by adding Na+ and Cl- ions to a concentration of ~50 mM. To allow 
for free protein rotation, the water box was de- fined as a cube with sides 80 Å, at least 
10 Å from the structure. The conformational stresses were removed using short steepest-
descent minimizations followed by simulated annealing until sufficient convergences 
were reached. Free dynamics simulations were run for 10 ns. Similar equilibration 
simulations were run for sLex (taken from the 1G1T PDB structure) with a water box of 
size 30 × 30 × 30 Å. The average structure for each simulation run was used for further 
simulation steps.  
Binding sLex to human and mouse E-selectin  
Molecular docking predicts the conformation of a protein-ligand complex and enables 
calculation of the binding affinity (221). sLex was docked to the human and mouse E-
selectin structures using the AutoDock program with YAMBER3 force field. sLex was 
allowed full flexibility and E-selectin had a fixed backbone with flex- ible sidechains. 
250 docking runs were completed, and the AutoDock scoring function sorted the runs by  
binding energy. Complex conformations were assumed to be different if the ligand 
RMSD was greater than 5 Å. Of the final conformations with positive binding energy, 
those for which there was no contact (5 Å or less) be- tween the fucose residue of sLex 
and the calcium ion were eliminated as they would not be physiologically realistic. The 
docked complexes were solvated using the same MD steps as before with a water box of 
size 100 × 100 × 100 Å. The distance from the ligand to the calcium ion was analyzed 
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over the simulation, and if it remained relatively constant, the complex was considered 
stable. The average free dynamics complex structures were used for the subsequent 
dissociation steps.  
SMD to simulate dissociation under applied force  
SMD was used to simulate dissociation under applied force. Constant acceleration was 
applied to the ligand center of mass to move it away from the receptor center of mass. 
The simulations were run until all the hydrogen bonds between sLex and E-selectin broke 
and the two proteins dissociated.  
Microtube functionalization  
Microrenathane tubes (300 μm i.d. and 50 cm long; Braintree Scientific, Braintree, MA) 
were sterilized with 75 % ethanol for 15 min. After three washes with PBS, the inner 
luminal surface was functionalized with recombinant human E-selectin (5 μg/mL) by 
incubating for 2 h, to allow for passive adsorption to the surface. Next, the microtubes 
were then incubated with dry milk powder (5 % w/v) in PBS for 1 h to prevent nonspecific 
adhesion. For control experiments, microtubes were pre- pared as indicated above except 
that E-selectin was replaced with BSA.  
Microsphere functionalization  
SuperAvidin-coated microspheres (9.94 μm diameter; CP01N, Bangs Laboratories, 
Fishers, ID) were washed with PBS buffer per manufacture instruction. Next, the 
microspheres were incubated with Sialyl-LewisX-biotin at specified concentrations for 1 
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h with gentle mixing every 15 min. Finally, the microspheres were washed twice and 
resuspended in flow buffer (PBS supplemented with 2 mM Ca2+). The surface density of 
sLex on the microspheres was not measured in this study, however our previous work 
with similar sLex-coated microspheres and selectin surface coatings show that these 
materials re- create the physiological rolling behavior of leukocytes in the vasculature, 
with comparable rolling velocities (222).  
Rolling experiment  
Functionalized microspheres (2x106/mL) suspended in flow buffer were perfused 
through the microtubes using a syringe pump at 8 dyne/cm2. Recorded videos of rolling 
microbeads were captured and analyzed using ImageJ similarly to prior publications (223, 
224).  
5.4 RESULTS  
Mouse E-selectin homology model exhibits a greater interdomain angle than human E-
selectin 
Human and mouse E-selectin structures were solvated and equilibrated over the course 
of 10-ns MD simulations. Three simulations were performed for each species; the average 
structures for each species over the MD simulations were examined and compared. The 
most prominent structural difference between the two species was the interdomain angle 
between the EGF and lectin geometric centers. The mean interdomain angle for hu- man 
E-selectin was 93.8° and the mean for mouse E- selectin was 104.8°, a difference of 11°. 
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Figure 5.2a shows overlaid representative human and mouse structures, and Figure 5.2b 
shows the interdomain angle quantification.  
Figure 5.3 shows the dynamic secondary structure by residue of each simulation run. The 
lectin domain for each species contains two α-helices: the C-terminal end of the first α-
helix is shorter by one or two residues for mouse E-selectin, and both species show some 
fluctuation, known as “fraying” (225), in the length of the second α-helix, particularly on 
the C-terminal end. The β- strands in the remainder of the lectin domain vary in length 
for both species. In the EGF domain, the main structural features are two antiparallel β-
strands. For the human runs 1 and 2, the beta-strands show little change in their length. 
In the human run 3, the two β-strands became fragmented into three after 2 ns. For the 
mouse, the β-strands show some variation in length for runs 1 and 2 but remain mostly 
stable for run 3. Overall, the mouse E-selectin lectin and EGF domains contains more 
random coil and turns than human E-selectin.  
Looking more specifically at the residue differences be- tween species, the average 
backbone root mean square deviation (RMSD) by residue was compared (Figure 5.4a). 
Mouse E-selectin exhibited a greater backbone RMSD across nearly all residues. 
Specifically, the regions 1–3, 6–8, 21–25, 41–42, 64–66, 79–87, 96–100, 118–121, 124–
126, 139, 145–151, and 153–157 showed a difference of more than 1 Å. Each of these 
regions contains amino acid differences between species. Importantly, many of these 
regions are involved with the pivot point between the lectin and EGF domains (226). The 
flexibility of each residue was compared between species by examining the root mean 
square fluctuation (RMSF). Figure 5.4b shows the RMSF by residue for each species, 
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averaged over the three runs. The RMSF by residue was nearly similar between human 
and mouse, but the mouse shows peaks at residues 21, 43, and 124 whereas the hu- man 
protein does not. As expected, these are all locations where there are one or more amino 
acid differences between species and all are locations of in- creased backbone RMSD 
(see Figure 5.4a). Residue 21 and 43 are at the C-terminal end of the first and second α- 
helices, respectively. As shown in Fig. 2, the length of both α-helices fluctuated over the 
equilibration MD simulation. Residue 124 shows the greatest increase in RMSF and is 
located in a section of turns and coils in the EGF domain that is roughly parallel to the 
main β- strands. Figure 5.4c shows the locations of two residues where there was the 
greatest difference in RSMD for the mouse E-selectin. Residue 22 is located very close 
to the lectin/EGF domain interface, and residue 85 is close the binding pocket in the lectin 
domain.  
Mouse E-selectin is predicted to bind more strongly to sLex than human E-selectin 
Equilibrated sLex was then docked onto the human and mouse E-selectin structures. The 
free energy of binding and the dissociation constant were ranked for each of the resulting 
complexes. Only stable complexes for which there was interaction with the calcium ion 
were considered (227), resulting in four feasible complexes for each species, and the 
highest free energy complex of each species was chosen for further study (228). The 
mouse E- selectin complex yielded a higher free energy of binding as well as a lower 
dissociation constant (Figure 5.5).  
Differences in dissociation time among complexes are caused more by interdomain 
flexibility rather than by contacts between receptor and ligand. 
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The complexes were solvated and equilibrated for 10 ns. The average equilibrated 
complexes were examined prior to dissociation as per other studies of selectin binding 
(229, 230). The geometric parameters analyzed included the distance and angle between 
the lectin and EGF domain centers of mass, the number of interdomain contacts and 
hydrogen bonds, the hinge distance, and the number of contacts and hydrogen bonds be- 
tween the ligand and the receptor. Contacts were de- fined as less than 5 Å distance 
between two residues. As shown in Fig. 6a, the mean interdomain angle for the mouse-
sLex complex was higher than for the human- sLex complex. Increased interdomain angle 
has been shown to increase flow-enhanced tether rate for N138G L-selectin (231), so it 
is predicted that mouse E-selectin will have a greater tether rate than human E-selectin. 
The secondary structure composition of both E-selectin species was examined (Figure 
5.6b). There was no significant difference in the percentage of α-helices and coil be- 
tween species. However, mouse E-selectin in complex had a smaller percentage of β-
strands and an increased percentage of turns compared with human E-selectin.  
The secondary structure of each complex was examined over the solvated free dynamics 
simulation (Figure 5.7). There was a notable difference in the antiparallel β- strands of 
the EGF domain between species. The mouse  
complex showed two such β-strands during each individual run and the length between 
the strands varied. However, all of the human complex runs oscillated be- tween two or 
three short β-strands. For both species, the two α-helices in the lectin domain showed 
some fluctuation in the length, particularly on the C-terminal end of the second α-helix; 
this is similar to the trajectories of E-selectin alone (Figure 5.2). The residue flexibility 
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of each species complex was examined by studying average RMSF values over the 10-ns 
free dynamics (Figure 5.8a). Comparing the two species, the mouse complex exhibited a 
higher RMSF at several key pivot residues, including 2, 30, and 125 (Figure 5.8b). There 
is also an RMSF peak at residue 43, which is at the C- terminal end of the second α-helix. 
Adhesion is largely regulated by the interdomain hinge, so increased flexibility in this 
area could indicate a prolonged bond lifespan and lower off-rate (218).  
The E-selectin residues in contact with sLex were examined for the average solvated 
1G1T structure and human and mouse configuration complexes (Figure 5.9). The human 
complex exhibited more contacts with sLex, defined as the number of atoms of E-selectin 
that were within 5 Å of any atoms of sLex. (Figure 5.9a). The specific residues and 
number of contacts for each complex are shown in Figure 5.9b. All of the E-selectin 
residues except residue 99 had RMSF values within 1 Å (Figure 5.8a), indicating 
relatively low flexibility. This is consistent with their location within or near the binding 
site. Residue 82 had the most contacts, with residues 97, 105, 107, and 111 showing the 
next highest number of contacts. There were several contacting residues in the human 
complexes that had no or negligible contact for the mouse complexes, including 47, 48, 
77, 78, 79, and 100. All of these residues had fewer than 50 contacts among the three 
runs. Conversely, two residues for which there was significantly more contact for mouse 
complexes than for human were 99 and 108 (Figure 5.9c). Both residues 99 and 108 
experienced about 100 contacts between the three mouse complexes; they are located on 
either end of the sLex and may serve as anchor points. Thus, despite having fewer total 
contacts and a similar number of resi- dues in contact with sLex, the data suggest that 
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residues 99 and 108 are of particular importance in dissociation. Residue 99 is lysine and 
residue 108 is arginine, both large and positively-charged amino acids. Neither of these 
are residues that are different between human and mouse E- selectin but both are one or 
two residues away from substitutions at 98, 101, and 110.  
Mouse E-selectin complex takes longer to dissociate than human E-selectin 
Each species complex was subjected to force loading rates between 2000 and 5000 
pm/ps2, and dissociation was determined as the point when all hydrogen bonds between 
the ligand and receptor were broken and did not reform. In all simulations, higher force-
induced loading rates led to faster dissociation times (Figure 5.10). Under all force-
induced loading rates, mouse complexes took longer on average to dissociate. However, 
only the rate of 3000 pm/ps2 led to a statistically significant dif- ference between species. 
sLex-coated microspheres were perfused through E- selectin coated microtubes and the 
average rolling vel- ocity of the microspheres on each E-selectin species were compared 
(Figure 5.11). Microspheres were used in- stead of cells to eliminate effects of cell 
deformability or other selectin:ligand pairs not considered within the scope of this study. 
As expected, the microspheres roll- ing on mouse E-selectin showed a statistically 
significantly lower rolling velocity compared to microspheres perfused over human E-
selectin; the average rolling vel- ocity on human E-selectin was 11.2 μm/s and the aver- 
age for mouse E-selectin was 0.63 μm/s. Rolling velocity is largely affected by off-rate 
(232), so the longer dissociation exhibited by simulations of the mouse E-selectin 
complex versus the human complex (Figure 5.0) is consistent with this trend.  
 
  90 
5.5 DISCUSSION  
Excessive leukocyte extravasation out of the blood- stream has been linked with chronic 
inflammation (216). Thus, potential therapies for controlling the inflammatory response 
could involve inhibiting or moderating the selectin adhesion that mediates leukocyte 
tethering and rolling to the blood vessel walls. Homology model- ing and amino acid 
substitutions, particularly those that affect molecular flexibility, and have been shown to 
be highly effective in changing adhesion and inhibitive function (233–235). In this study, 
a mouse homology model comprising 29 point substitutions to the human E-selectin 
crystal structure greatly affected dissociation of sLex from the resulting complex. The 
adhesive characteristics of the mouse E-selectin homology model qualitatively match 
results from experiments that showed slower rolling velocity of sLex-coated 
microspheres. These results provide new insight into the connection be- tween structure 
and function of species-specific E-selectin. These results suggest that differences in 
dissociation time result more from interdomain flexibility than by contacts between 
receptor and ligand. Docking a homology model structure does accumulate more errors 
than using a crystal structure (236), but in this case, a crystal structure for mouse E-
selectin was not available. The docking algorithm accounts for two import- ant details: 
protein flexibility is a key determinant in binding, and physiologically, complexes are 
solvated in a salt solution (227). The docking algorithm included flexibility in the E-
selectin side chains and full flexibility in the sLex.  
The docked structures were solvated after docking using 10-ns MD simulations to allow 
for more physiological conditions. Intramolecular distortion of the lectin and EGF 
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domains was not evident for most simulations, particularly at higher force-induced 
loading rates. It has been shown that shear flow can have a contribution to intramolecular 
distortion (230), but as with most selectin:ligand dissociation simulations (136), shear 
flow is not directly considered in these SMD simulations.  
This study demonstrates the significance of combining simulations with experimental 
rolling studies to gain in- sights into the functional differences between proteins that share 
sequence similarity. The differences in amino acid structure can be exploited for 
applications such as selectin-based leukocyte and circulation tumor cell isolation (176). 
The combined methodology involving docking,  
5.6 CONCLUSION  
Molecular simulations were used to elucidate the binding of sLex to mouse and human 
E-selectin. Docking simulations predicted that mouse E-selectin would bind more 
strongly to sLex than human E-selectin, and SMD simulations predicted that the mouse 
E-selectin:sLex complex would exhibit a longer dissociation time. Mouse E-selectin 
alone and bound to sLex exhibited a greater interdomain angle than human E-selectin, 
and there were fewer receptor:ligand contacts. When tested experimentally, sLex-coated 
microspheres rolled more slowly in tubes coated with mouse E-selectin rather than human 
E-selectin.  
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Figure 5.1: Sequence alignment of EGF and lectin domains of human and mouse E-
selectin. The lectin domain is shown in green, and the EGF domain is shown in teal. 
Residue differences between species are noted in red, and the binding pocket for human 
E-selectin is noted in yellow and underlined. Adapted from A. Rocheleau, T. Cao et al. 
BMC Structural Biology (2016). 
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Figure 5.2: Mouse E-selectin showed a greater interdomain angle than human. a Mouse 
E-selectin is shown in blue and human E-selectin is shown in red. b The angle is measured 
from geometric center of residues 1–118 to the geometric center of residues 119–157 with 
a hinge at the pivot. Mean and standard deviation are plotted. Calcium ion is shown in 
yellow. *P value < 0.05 (two-tailed t-test). Adapted from A. Rocheleau, T. Cao et al. BMC 
Structural Biology (2016). 
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Figure 5.3: Dynamic secondary structure by residue of human and mouse E-selectin over 
10 ns MD simulations. Residues are labeled by secondary structure according to their 
color: α-helices are red, β-strands are blue, 3–10 helices are grey, and coils and turns 
are not colored. The lectin domain includes residues 1–118, and the EGF domain is 119–
157. Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology (2016). 
 
 
 
 
 
 
 
 
  95 
 
Figure 5.4: Residue differences between human and mouse E-selectin. Average backbone 
RMSD by residue (a) and average RMSF by residue (b)of human and mouse E-selectin 
during 10 ns MD simulations. c Mouse structure showing locations of residues 22 near 
the domain interface and 85 near the binding pocket. Adapted from A. Rocheleau, T. Cao 
et al. BMC Structural Biology (2016). 
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Figure 5.5: Free energies of binding and dissociation constants for human and mouse E-
selectin:sLex complexes. Free energies of binding are shown with green circles and a 
solid line and dissociation constants are shown with purple squares and a dashed line. 
Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology (2016). 
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Figure 5.6: Differences in domain angle and secondary structure composition between 
species. a Angle between geometric center of residues 1–118 and geometric center of 
residues 119–157 for human and mouse complex configurations. b Secondary structure 
composition of E-selectin by species. Mean and standard deviation are shown. *P < 0.05 
(two-tailed t-test). Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology 
(2016). 
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Figure 5.7: Dynamic secondary structure by residue of human and mouse E-selectin 
complexes over 10 ns MD simulations. Residues are labeled by secondary structure 
according to their color: α-helices are red, β-strands are blue, 3–10 helices are grey, and 
coils and turns are not colored. The lectin domain includes residues 1–118, and the EGF 
domain is 119–157. Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology 
(2016). 
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Figure 5.8: Interdomain hinge differences between species. a RMSF by residue for human 
mouse configuration complexes. b Mouse structure showing locations of residues 2, 30, 
and 125 near the domain interface. Adapted from A. Rocheleau, T. Cao et al. BMC 
Structural Biology (2016). 
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Figure 5.9: Receptor/ligand interface differences between human and mouse complexes. 
a Number of contacts between ligand and receptor within 5 Å. Mean and standard 
deviation are shown. *P < 0.05 (two-tailed t-test). b Distribution and quantification of 
receptor/ligand contacts for E-selectin residues that are within 5 Å of sLex for each 
human and mouse complex. c Mouse E-selectin looking down on lectin domain, showing 
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locations of residues 99 and 108 relative to sLex. Adapted from A. Rocheleau, T. Cao et 
al. BMC Structural Biology (2016). 
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Figure 5.10: Dissociation time for mouse:sLex and human:sLex complexes at varying 
force-induced loading rates. Mean and standard deviation are shown. *P < 0.05 (two-
tailed t-test). Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology (2016). 
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Figure 5.11: Rolling velocity of sLex-coated microspheres perfused through an E-selectin 
coated microtube. Mean and standard deviation shown. ***P < 0.001 (two-tailed t-test). 
Adapted from A. Rocheleau, T. Cao et al. BMC Structural Biology (2016). 
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CHAPTER 6 
Stabilization of the Hinge Region of Human E-selectin Enhances  
Binding Affinity to Ligands Under Force   
This chapter is in submission in the Scientific Report.
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6.1 ABSTRACT 
E-selectin is a member of the selectin family of cell adhesion molecules expressed on 
the plasma membrane of inflamed endothelium and facilitates initial leukocyte 
tethering and subsequent cell rolling during the early stages of the inflammatory 
response via binding to glycoproteins expressing sialyl LewisX and sialyl LewisA 
(sLeX/A). Existing crystal structures of the extracellular lectin/EGF-like domain of E-
selectin complexed with sLeX have revealed that E-selectin can exist in two 
conformation states, a low affinity (bent) conformation, and a high affinity (extended) 
conformation. The differentiating characteristic of the two conformations is the 
interdomain angle between the lectin and the EGF-like domain. Using molecular 
dynamics (MD) simulations we observed that in the absence of tensile force E-selectin 
undergoes spontaneous switching between the two conformational states at 
equilibrium. A single amino acid substitution at residue 2 (serine to tyrosine) on the 
lectin domain favors the extended conformation. Steered molecular dynamics (SMD) 
simulations of E-selectin and PSGL-1 in conjunction with experimental cell adhesion 
assays show a longer binding lifetime of E-selectin (S2Y) to PSGL-1 compared to 
wildtype protein.  The findings in this study advance our understanding into how the 
structural makeup of E-selectin allosterically influences its adhesive dynamics.  
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6.2 INTRODUCTION 
E-selectin belongs to a family of cell adhesion (E-, L-, and P-) molecules that are 
responsible for leukocyte recruitment to inflammation sites (237). E-selectin is a Ca2+-
dependent lectin glycoprotein that is expressed on the plasma membrane of activated 
vascular endothelial cells by pro-inflammatory stimuli (149). Beyond its well-
characterized role in leukocyte trafficking, E-selectin is also involved in integrin 
activation, hematopoietic stem cell homing to the bone marrow, and cancer metastasis 
(68, 145, 238–241). All selectins have a C-type lectin domain at the extracellular N-
terminus containing a binding pocket that recognizes glycoproteins and glycolipids 
decorated with tetrasaccharide sialyl LewisX and sialyl LewisA (sLeX/A) (242). Known 
E-selectin’s ligands include P-selectin glycoprotein ligand-1 (PSGL1), CD43 and CD44 
expressed on various human leukocyte subpopulations, and E-selectin ligand-1 (ESL-
1) present on mouse myeloid cells (243–245). Connecting to the lectin domain is an 
epidermal-growth-factor (EGF-like) domain, followed by varying units of short 
consensus repeats  (SCRs), a transmembrane portion and ending with a cytoplasmic tail 
(149). Structural studies of selectins suggest that the molecules can exist in two 
conformational states: a low affinity (bent) conformation and a high affinity (extended) 
conformation (159, 246–248). The defining characteristic differentiating the two 
conformational states is the interdomain angle of the hinge region, the interdomain 
region connecting the lectin to the EGF-like domain. The hinge region of selectin is of 
the focus in this study because of its allosteric modulation of selectin binding mechanics 
(249, 250). Here we show a single amino acid substitution at the hinge region can alter 
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the overall macromolecular characteristics of E-selectin resulting in altered binding 
kinetics to ligands. The data supporting this observation will be discussed in this article. 
Effective leukocyte trafficking in the vascular microenvironment under physiological 
shear flow requires that selectins are able to bind to ligands very quickly by having a 
fast on-rate. In addition, the subsequent selectin/ligand complex must able to withstand 
the pressure of the tensile stress. Selectin binding exhibits what is known as “catch-
bond” behavior in which receptor/ligand bond formation requires a minimum threshold 
level of shear (251–253). The bond is further strengthened as the tensile force increases 
until the force becomes too great, and the bond becomes an ordinary “slip-bond”.  
Previous studies have put forth multiple models linking the structural architecture of 
selectin’s conformational states to their catch-bond behaviors. For instance, in the 
“sliding-rebinding” model described by Lou et al., it is postulated that the flexibility of 
the hinge region in L-selectin allows it to adopt two different conformations: a low 
affinity (bent) conformation in the absence of force and a high affinity (extended) 
conformation in the presence of force (218, 254). In the extended conformation, the 
binding surface is aligned with the direction of the force which allows bound ligands to 
slide along the binding interface and continuously rebuild or form new interactions, 
causing a high affinity conformation. Selectin crystal structures also revealed significant 
structural displacement at the binding interface when the molecule adopts different 
conformational states, which suggests an allosteric relationship between the hinge 
region and the binding interface (255). However, the “sliding-rebinding” model does 
not address this allosteric relationship. Alternative theories have been proposed linking 
the force-induced extension of selectin molecules and allosteric changes in the ligand 
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binding interface (226, 255). In the “prybar” model, residue 1W of the lectin domain 
and the EGF-like domain of L-selectin together form an L-shaped lever that is held 
together by a network of hydrogen bonds when the molecule is in the bent conformation. 
When force is applied and L-selectin transitions to the extended conformation, the lever 
dislodges the relatively large and hydrophobic residue, 1W, which causes a cascade of 
residue displacements resulting in the allosteric change of the binding interface to a 
high-affinity conformation.  
In different species, the same selectin molecules share a high degree of amino acid 
sequence homology: ~72% and ~60% of amino acid sequence are conserved for the 
lectin and EGF-like domain, respectively (149). The high degree of inter-species 
sequence homology enables mouse E-selectin to readily cross-react to human ligands 
and vice-versa (213, 256). More interestingly, mouse E-selectin exhibits significantly 
higher affinity to human ligands than human E-selectin. This observation can be 
explained in part by molecular dynamics (MD) simulations that found mouse E-selectin 
to have a greater interdomain angle than its human counterpart, suggesting that mouse 
E-selectin favors the high-affinity extended conformation (213). However, individual 
amino acid variances of E-selectin between human and mouse species and their 
influence on ligand binding kinetics remain largely unexplored. The goal of this study 
was to gain new insight into E-selectin conformational states, their corresponding ligand 
binding characteristics, and how strategic structural modifications of E-selectin can 
modulate its macromolecular behavior. Using MD simulations, we predicted possible 
E-selectin structural transitions between conformational states and their effects on the 
binding interface. We also looked at the network of non-covalent interactions 
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distributed over the hinge region associated with these conformational changes. Next, 
we introduced a key point mutation at the hinge region and examined the dynamic 
changes over time on E-selectin/PSGL-1 complex in the presence of a pulling force that 
was applied to induce unbinding. In conjunction with computational modelling, 
experimental cell rolling assays were used to substantiate our MD results. 
6.3 METHODS 
Molecular Dynamics (MD) Simulation   
The bent and extended crystal structures of E-selectin (1G1T, 4CSY (159, 247)), were 
obtained from the Protein Data Bank for use as starting atomic coordinates. Free-
dynamics and steered molecular dynamics (SMD) simulations were performed using 
the YASARA (http://yasara. org) package of MD programs with the YAMBER3 self-
parameterizing force field. For all simulations, the temperature and pressure were held 
constant at 300 K and 1 atm, respectively. Periodic boundary conditions, the particle 
mesh Ewald method for electrostatic interactions, and the recommended 7.86 A ̊ force 
cutoff for long-range interactions were also used. Predicted structures of PSGL-1 bound 
to E-selectin were obtained by aligning E-selectin (1G1T, 4CSY) crystal structures on 
the P-selectin/PSGL-1 complex (1G1S, subunit a) via the MUSTANG algorithm. All 
simulations were run at least 4 times with different starting velocities. 
Principle Component Analysis (PCA) of MD simulations was performed with Bio3D, 
and R software packaged developed by the Grant lab (264). Cartoon renditions of E-
selectin was created with UCSF Chimera, an extensible molecular modelling system, 
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developed by the UCSF Resource for Biocomputing, Visualization, and Informatics 
(265).  
Cell lines and cell culture  
The acute myeloid leukemic KG-1a cell line (ATCC number CCL-264.1) was 
purchased from ATCC (Manassas, VA) and cultured in RPMI 1640 media 
supplemented with 2 mM L-glutamine, 25 mM HEPES, 10% (v/v) FBS, and 100 U/mL 
penicillin-streptomycin at 37C and 5% CO2. Cultured cells were regularly test for 
mycoplasma using Universal Mycoplasma Detection Kit (ATCC 30-1012K). 
Microtube functionalization  
The microtubes were functionalized using methods, as previously described (61, 168). 
Briefly, micro-renathane (MRE) tubes (300 mm i.d.; Braintree Scientific, Braintree, 
MA) were sterilized with 75% ethanol for 15 min. After three washes with phosphate 
buffer saline (PBS) (Ca2+ and Mn2+ free), the microtubes were incubated with Protein 
G (2 µg/mL PBS) for 1 h. Next, the luminal surface was functionalized with chimeric 
human E-selectin (W/T, S2Y, S2W, S2C) at 5 µg/mL for 2 h. The microtubes were then 
incubated with dry milk powder (5% w/v) in PBS for 1 h to minimize nonspecific 
adhesion. For control experiments, microtubes were prepared as indicated above except 
that the adhesion molecule was replaced with bovine serum albumin (BSA).  
Cell adhesion assay  
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Cell rolling experiments were conducted using methods as previously described (136). 
KG-1a cells were suspended in flow buffer (PBS supplemented with 2 mmol Ca2+) at 
the concentration of 106 cells/mL. Cell suspension was perfused through functionalized 
microtubes using a syringe pump at specified wall shear stresses. Videos were recorded 
for 1 min at 5-10 random locations along the length of the microtube after 5 min of 
perfusion for each shear stress.  
Data acquisition 
Rolling cells were recorded using a microscope-linked Hitachi CCD camera KP-M1AN 
(Hitachi, Japan) and a Sony DVD Recorder DVO- 1000MD (San Diego, CA). Rolling 
velocity was determined using ImageJ (U.S. National Institutes of Health, Bethesda, 
MD). Rolling cells were defined as a cell translating along the surface for >2 s at a 
velocity <50% of the free stream velocity of a noninteracting cell. The average rolling 
velocity was calculated from at least 30 rolling cells. Cell rolling experiment was done 
in triplicates for statistical analysis. Two-tailed unpaired t-tests were used to analyze 
result 
6.4 RESULTS  
E-selectin spontaneously transitions between the bent and extended conformations at 
equilibrium 
Existing structural data suggest that selectins adopt two conformational states: a low 
affinity (bent), and a high affinity (extended) conformation. Furthermore, MD 
simulations predicted  that L-selectin can undergo conformation switching in the 
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absence of force (172). To determine if E-selectin exhibits spontaneous conformational 
change between the two conformational states in the absence of force, we simulated the 
molecule, as previously described (136), using the published crystal structures of the 
two known conformational states (bent - 1G1T, extended - 4CSY) as starting 
coordinates. Principal component analysis (PCA), a dimensionality reduction technique 
(257, 258), was used to transform the original high-dimensional representation of 
protein motion in MD simulations into a lower dimension representation that reveals 
the dominant structural dynamics of proteins. The vibrational fluctuation of the 
molecules over a period of 50 ns of simulation time was reduced to two Principal 
Components (PC 1, PC 2), which attributed for over 78% of total protein movement 
(Figure 6.7). The greatest fluctuation was observed in the EGF-like domain (residues 
129-) (Figure 6.1a). In addition, the two domains moved in opposite directions of one 
another. In the lectin domain, the flexible region adjacent to the hinge region, and the 
flexible loop (residues 83-89) at the binding pocket also showed a high degree of 
fluctuation (Figure 6.1a). Tracing the trajectory of the structural displacement of the 
simulation of 4CSY (extended) we observed that the molecule spontaneously 
transitioned from the bent to extended conformation and back (Figure 6.1b). RMSD 
traces of the simulations of either 4CSY (extended conformation) or 1G1T (bent 
conformation) showed conformational changes occurring at 10 and 20 ns, respectively 
(Figure 6.1c). These conformational changes correlated with the opening and closing of 
the hinge region as indicated by the opening and closing of the interdomain angle 
(Figure 6.1d). 
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A dynamic network of hydrogen bonds at the interdomain hinge region stabilizes the 
conformational states 
A closer examination of the flexible interdomain hinge region during the oscillation 
between the bent and extended conformational states, revealed a dynamic hydrogen 
bond network. Figure 6.2 shows three representative simulation time points of a MD 
simulation of E-selectin transitioning from a bent to an extended conformation and back. 
Looking directly down the X-axis of E-selectin protein, there existed a network of 
hydrogen bonds (H-bond) that stabilizes the interdomain region on both sides of the 
molecule.   At time = 0, when the molecule is in the bent conformation and the 
interdomain angle is at its minimum, residue Q30 of the lectin domain hydrogen bonds 
with E135 of the EGF-like domain. This stabilizes E-selectin in the bent conformation 
(Figure 6.2a). Residue E34 formed an H-bond to residue Q30, thus keeping the residue 
facing in close proximity to residue E135. This further promotes its interaction with 
residue E135. On the opposite side of the molecule, residue N138 of the EGF-like 
domain exhibited multiple hydrogen bonds with residues on the lectin domain: residue 
Y37 and the carboxyl oxygen of residue W1. This network of hydrogen bonds between 
the lectin and the EGF-like domain collectively maintains E-selectin in a bent 
conformation. 
As E-selectin shifted towards the extended conformation and the interdomain angle 
became larger (Figure 6.2b), residue E34 shifted to the right and away from Q30 and no 
longer hydrogen bonded to residue Q30, allowing residue Q30 to rotate upward and 
away from EGF-like domain. Thus, residue Q30 no longer interacted with residue E135, 
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which also shifted to the right. As the loop region was moving away, residue W1 swung 
downward and towards the right which then hydrogen bonded with residue E135 
(shifted far to the right) and residue Y37. Most noticeably, residue S2 flipped its 
orientation towards the front and then formed a hydrogen bond with residue N138. The 
disproportional distribution of hydrogen bonds present here favors the extended 
conformation. 
At t = 30 ns, E-selectin reverted back to the bent conformation (Figure 6.2c). On the left 
side of the interdomain region, residue Q30 re-rotated back downward and towards the 
front, bringing it, again, closer to EGF-like domain. Residue W1 swung upward and to 
the left.   
The dynamic breaking and formation of hydrogen bonds and the amino acid residues 
involved as E-selectin transitions between conformational states suggest that these 
amino acids, to varying degrees, influence the macromolecular structure of E-selectin. 
A substitution of residue 2 (S2Y) eliminates spontaneous transitioning between the two 
conformational states. 
There exist 20 amino acid differences within the lectin domain between human and 
mouse E-selectin (213). Of these 20 variations, only residue number 2 (S2) of the lectin 
domain is located in the hinge domain and is involved in noncovalent interaction with 
residues in the EGF-like domain as pointed out in Figure 6.2. Serine is a smaller amino 
acid, and its side chain consisting of a hydroxyl group that can noncovalently react with 
other molecules. On the mouse E-selectin molecule, the serine residue is replaced with 
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a much larger tyrosine residue that also has a distal hydroxyl group on its sidechain 
which can readily form H-bonds with asparagine residues (N138 and N139) on the EGF-
like domain (Figure 6.3a). Based on the simulation results suggesting that interactions 
between residue 2 and other residues on the EGF-like domain favor the extended 
conformation, we postulated that a S2Y point mutation of the human E-selectin 
molecule would cause the molecule to favor the high affinity extended conformation 
over the lower affinity bent conformation. To test this hypothesis, we simulated human 
E-selectin (S2Y) in the similar fashion to the wildtype counterpart, E-selectin (W/T). 
The S2Y point mutation effectively abolished any spontaneous transitioning of E-
selectin between conformational states, as evident by the RMSD trace and the 
interdomain angle measurements (Figure 6.3b and c). The E-selectin (S2Y) molecule 
remained in the high affinity extended conformation throughout the entire simulation. 
High affinity extended conformation allosterically forces the binding pocket to also 
adopt a high-affinity conformation in E-selectin 
Conformational changes in the hinge region of selectins can allosterically induce 
conformational changes to the binding region (172, 259). We compared the structural 
changes occurring in our simulations between the two E-selectin variants. RMSF trace 
over the simulation time revealed significantly higher residue fluctuations at the flexible 
loop containing residues 81-85 for E-selectin (W/T) compared to E-selectin (S2Y) 
(Figure 6.4a). This flexible loop which is located at the binding pocket and its amino 
acids are involved in ligand binding (149). For the wildtype E-selectin, the loop 
alternated between high-affinity and low-affinity conformation which reduced the 
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overall exposure time these amino acid residues to the bound ligand (Figure 6.4b). 
Conversely, for simulations involving E-selectin (S2Y), the same flexible loop 
remained for almost the entire simulation time in the high-conformation state. 
E-selectin (S2Y) exhibits higher binding affinity to its ligand than wildtype E-selectin 
To test our hypothesis that a single amino acid substitution (serine to tyrosine) at residue 
2 of E-selectin would allosterically extend the binding lifetime of E-selectin to PSGL-
1, we used steered molecular dynamics (SMD) simulations to manually dissociate 
PSGL-1 away from E-selectin like previously described (136, 213). Figure 6.5 
illustrates the amount of simulation time of a representative simulation necessary before 
PSGL-1 is completely dissociated from E-selectin (W/T and S2Y), as defined by the 
distance at which non-covalent intermolecular interactions between the two molecules 
are no longer observed. The SMD simulation showed that PSGL-1 completely 
dissociated from E-selectin (W/T) significantly faster than with E-selectin (S2Y) at 
approximately 70 ps and 95 ps, respectively (Figure 6.5a). Four SMD simulations were 
performed with different initial velocities for E-selectin (W/T or S2Y)/PSGL-1 
complex. The average dissociation times were 52.5 ± 14.3 ps and 71.3 ± 23.5 ps for 
wildtype E-selectin and E-selectin (S2Y), respectively. The longer binding time 
between PSGL-1 and E-selectin (S2Y) was likely the result of the flexible loop at the 
binding pocket remaining in close proximity to PSGL-1, thus allowing residues R84 
and Q85 to experience prolonged interactions with the fucose residue on PSGL-1. At 
10 ps after the initial pulling of PSGL-1 away from E-selectin, the flexible loop 
containing residues R84 and Q85 in E-selectin (WT) already starting to fold away from 
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the binding pocket resulting in residues R84 and Q85 to stop interacting with PSGL-1 
(Figure 6.5b, top left panel). Conversely, the same flexible loop in E-selectin (S2Y) was 
still facing into the binding pocket, allowing residues R84 and Q85 to maintain multiples 
contacts with the fucose molecule on PSGL-1 (Figure 6.5b, bottom left panel). 
Furthermore, PSGL-1 also maintained multiple interactions with E-selectin (S2Y) 
outside of the binding pocket including: residue E107 with the galactose, and serine 
residues (S45, S47) with the sulfated tyrosine (TYS161) on PSGL-1. These interactions 
were absent in the simulation involving E-selectin (W/T). At 50 ps, the flexible loop 
inside the binding pocket of E-selectin (W/T) had completely folded away from PSGL-
1, further weakening the interaction between the two molecules (Figure 6.4b, top right 
panel). This is evident from the increase in dissociation distance rate that followed 
(Figure 6.5a). Comparing to its wildtype counterpart, the E-selectin (S2Y) still 
maintained multiple interactions with PSGL-1 in the binding pocket, including residue 
R84 interacting with one of the oxygen species of the fucose molecule on PSGL-1 
(Figure 6.4b, bottom right panel). 
To further corroborate the SMD simulation results, we experimentally assessed the 
effect of the point mutation (S2Y) on E-selectin’s ligand affinity. We performed a cell 
rolling assay using model cell line KG-1a, in microtubes coated with the indicated E-
selectin/Fc chimeric molecules and under a range of physiological shear stresses as 
previously described (136, 176). KG-1a is a leukemic cell line expressing abundant 
selectin ligands on its surface, and is a commonly used model cell line in rolling assays 
for studies involving selectin ligand binding mechanics (61, 195). Human E-selectin/Fc 
chimeric protein was created and purified from HEK  293 cells. Variants of wildtype 
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including E-selectin (S2Y, S2W, and S2C) were also created and purified to assess the 
allosteric effect of the hinge on E-selectin binding behavior. The average rolling 
velocities of KG-1a cells were significantly lower on surfaces coated with E-selectin 
(S2Y) at all levels of shear stress compared to E-selectin (W/T) (Figure 6.6). This is 
indicative of E-selectin (S2Y)’s enhanced ligand binding compared to the wildtype. We 
expected the capability of the tyrosine residue to hydrogen bond to asparagine residues 
in the EFG-like domain would shift the equilibrium in favor of the high affinity extended 
conformation. Therefore, we also examined the rolling velocity of KG-1a cells on 
surfaces coated with E-selectin (S2W). Tryptophan (W) is similar to tyrosine in 
structure, as it is also a bulky amino acid that has an aromatic ring. However, it cannot 
hydrogen bond to residues 138 and 139 because it lacks the functional OH group. As a 
result, the rolling velocity profile of KG-1a was observed to be very similar to that of 
the wildtype. We also looked at the rolling profile of cells on surfaces coated with E-
Selectin (S2C). Cysteine has a similar structure to serine but has a sulfur in place of an 
oxygen atom at the gamma location. Not surprisingly, the rolling profile of KG-1a on 
this surface was also similar to that on the wildtype. The experimental data support our 
theory that a S2Y substitution favors the high affinity extended conformation in E-
selectin.          
6.5 DISCUSSION 
The two-state kinetic model of selectin’s catch bond behavior postulates that, in the 
absence of force, selectins may exist in two interchanging conformational states at 
equilibrium (231, 260). When tensile force is applied, selectins favor the high affinity, 
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extended conformation. This theory is supported by structural studies of E- and P-
selectin and computational modelling of L-selectin (159, 218, 246, 247). Here, our MD 
simulation data of E-selectin also predicts that the molecule does indeed follow the two-
state model, as observed by the molecule’s spontaneous transitioning between the bent 
and extended conformational states (Figure 6.1). Furthermore, we observed 
conformational change in 3 out of the 4 simulation runs we performed for each starting 
coordinate (bent and extended). An observed 75% occurrence rate in our simulations is 
higher than that seen by Lou et al. (~30%) in their MD simulation of L-selectin. The 
frequency increase may be explained by the extended simulation time of 50 ns in our 
simulations, compared to 6 ns in the previous study (218). In a more recent study by 
Preston et al. using small angle X-ray scattering (SAXS) measurement, they found that 
in the absence of force, ligand binding to E-selectin alone can allosterically shift the 
equilibrium to favor the high-affinity, extended conformation (247). This observation is 
in contrast to earlier assertions that tensile force is required to shift the conformational 
equilibrium towards the extended conformation (226). More importantly, these 
seemingly contradicting observations emphasize that while our understanding of 
selectin mechanochemistry is expanding, it is still incomplete. Although it was not 
explored in this study, it would be interesting in future studies to use MD techniques 
such as docking to determine if ligand binding alone can trigger an allosteric structural 
change from the bent to extended conformation in selectins. 
Interaction between the lectin and EGF-like domain of selectins is limited in the number 
of contacts, as observed in published crystal structures and the results presented here 
(13, 14, Figure 6.2). The small number of interactions between the two domains 
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supports the theory that the hinge region of selectins is inherently flexible, suggesting 
that thermodynamically the molecule can readily transition between conformational 
states at equilibrium. Moreover, by modulating the degree of flexibility of the hinge 
region, one may influence the conformational equilibrium of selectin. This idea was 
previously explored in P-selectin which showed that locking P-selectin in the extended 
conformation can increase its adhesiveness to ligands under hydrodynamic force (172). 
In addition, others have introduced an N138G substitution on the EGF domain of L-
selectin, and showed that replacing a bulky asparagine residue with a smaller glycine 
residue, can stabilize the high affinity extended conformation of L-selectin (172, 218, 
226). Here we investigated the stabilizing effect of single amino acid substitution at 
residue 2 (S2Y) on the lectin domain of E-selectin. While human and mouse E-selectin 
share considerable sequence homology, there exist 20 amino acid variances in the lectin 
domain that may, to varying degrees, contribute to enhanced affinity seen in mouse E-
selectin to human ligands (213). Whereas residue 2 in human E-selectin is serine, mouse 
E-selectin has a relatively bulkier amino acid tyrosine at residue 2. A serine to tyrosine 
substitution of human E-selectin led to significant decrease in rolling velocity of KG-1a 
cells on surface coated with E-selectin across a range of shear stresses, an indication of 
stronger ligand affinity (Figure 6.6). The bulky aromatic ring of tyrosine forces the 
amino acid to adopt the most energetically favorable orientation, facing away from the 
lectin domain and with its distal OH group pointing at residues N138 and N139 (261). 
In the bent conformation, neither serine nor tyrosine interacts with residues in the EGF 
domain. However, when E-selectin is in the extended conformation, only the larger 
tyrosine residue is able to make sidechain hydrogen bonds with residues 138 and 139 
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on the EGF domain at high frequency.  We hypothesized that during one of E-selectin 
spontaneously transition from bent to extended conformation, the S2Y substitution 
affords more opportunity of H-bond formation with residues 138 and 139 on the EGF 
domain. As a result, the conformation equilibrium favors the extended conformation. 
The absence of conformational change in simulations for E-selectin (S2Y) using the 
extended conformation as starting coordinates supports this hypothesis (Figure 6.3). 
Furthermore, SMD simulations of E-selectin/PSGL-1 complex showed extended 
binding for E-selectin (S2Y) compared to the wildtype. Collectively these results 
suggest the importance of allosteric dependence of the hinge region on the binding 
mechanics of selectins. A better understanding of selectin structure and its influence on 
ligand binding can be applicable to other receptor/ligand complexes that exhibit the 
similar catch-bond behavior.   
It is important to note that we did not observe in our simulations of E-selectin (S2Y) 
with the bent conformation as starting coordinates the molecule spontaneously 
transition to the extended conformation and remain so. This was not completely 
unexpected given the limitations of MD simulations. MD simulation time scale 
represents only a tiny fraction of the biological time scale. Therefore, extended 
simulation time covering multiple conformational switching would be necessary to 
produce a truly comprehensive representation of protein biomechanics at the biological 
time scales. Ultimately, MD simulation time is limited by computing power. Moreover, 
current molecular mechanics force fields used by many MD simulations do not fully 
capture the directional dependence of hydrogen bonds (262, 263). This makes modelling 
selectins, with their extensive and complex hydrogen networks a continuing challenge.
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Figure 6.1: E-selectin spontaneously transitions from bent to extended 
conformational state and back again. (A) MD trajectory representations of E-
selectin during the least displacement and the highest displacement, respectively. 
(B) PC1 vs PC2 shows the predicted transitioning path of E-selectin from bent, to 
extended, and back to bent. (C) RMSDs of MD simulations as a function of time. 
(D) Angle measurement of the interdomain hinge region as a function of time. (E) 
Ribbon representations of E-selectin and the measured angle at t = 10 ns and t = 
30 ns. (Blue = lectin domain, Pink = EGF -like domain). 
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Figure 6.2: Dynamic hydrogen network stabilizes the interdomain hinge 
region. Representative illustrations of human E-selectin MD simulations 
at indicated time pointsshowing the formation and breakage of hydrogen 
bond network as the protein transitions from the bent to the extended 
conformation and back again at the interdomain region. Yellow dashed 
lines represent hydrogen bonds; Red arrows indicate trajectories of 
indicated residues. 
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Figure 6.3: Point mutation of residue 2 from Serine to Tyrosine eliminates the 
spontaneous transition between the two conformational states. 
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Figure 6.4: High affinity extended conformation allosterically forces the binding pocket 
to also adopt a high-affinity conformation in E-selectin. (A) RMSF per residue of the 
lectin domain of wildtype E-selectin (W/T) and variant E-selectin (S2Y). Grey rectangle 
highlights the flexible loop containing residues 83-85 of the binding pocket. (B) 
Schematics of flexible loop outlining the reduction of fluctuation in E-selectin (WT) 
compared to E-selectin (S2Y).    
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Figure 6.5: SMD simulations show PSGL-1 has higher affinity to E-Selectin (S2Y) than 
E-Selectin (W/T). (A) SMD simulation showing the dissociation time (in simulation 
time) of PSGL-1 from E-Selectin.  (B) Representative illustrations of human E-selectin 
interaction with PSGL-1 as it is being pulled away from E-Selectin at the indicated time 
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points. E-selectin is blue; PSGL-1 is grey. Purple lines are representative of inter-
molecular interactions. 
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Figure 6.6: E-selectin (S2Y) has increased adhesiveness to ligands compared to the 
wildtype. The average rolling velocity of model cell line, KG-1a, ligands rolling on 
microtubes coated E-selectin-Fc chimeric protein.  
    wildtype,     S2Y,     S2W,      S2C; n = 3) 
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Figure 6.7: Proportion Percentage of the 
20 Largest Eigenvalues (PCs).  A 
representative distribution (%) of the 20 
Largest Eigenvalues encapsulating the 
total displacement perturbation of an 
MD simulation of E-selectin. 
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